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AC: Acid ceramidase 
AKT: serine/threonine kinase also known as protein kinase B (or PKB) 
ANOVA: analysis of variance 
AML: Acute myeloid leukemia 
ASMase: Acid sphingomyelinase 
 
BSA: Bovine serum albumin 
B56γ: PPP2R5C regulatory subunit of Protein Phosphatase 2A 
B56d: PPP2R5D regulatory subunit of Protein Phosphatase 2A 
 
C1P: Ceramide-1-phosphate 
C6P: D-erythro-C6 pyridinium ceramide 
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CERT: Ceramide transfer protein 
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CML: Chronic myeloid leukemia  
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D-e-C18: D-erythro-C18 ceramide 
DES: Dihydro-ceramide desaturase 
DMEM: Dulbecco’s Modified Eagle Medium 
DOSY: Diffusion Ordered Spectroscopy 
eNOS: endothelial nitric oxide sunthase 
ER: Endoplasmic reticulum 
 
FTY720: Fingolimod, Gleevec  
FPLC: Fast Protein Liquid Chromatography  
 
HDAC: Histone deacetylase 
 
GA: Glutaraldehyde 
GCS: Glucosylceramide synthase 
 
I2PP2A/SET: Inhibitor 2 of PP2A 
INHAT: inhibitor of histone acetyltransferases 
ITC: Isothermal Titration Calorimetry 
 
L-e-C18: L-erythro-C18 ceramide 
 
MOE: Molecular Operating Environment 
 
NMR: Nuclear Magnetic Resonance 
NOESY: Nuclear Overhauser Enhancement Spectroscopy 
NSMase: Neutral sphingomyelinase 
PCR: Polymerase Chain Reaction 
PDI: Protein disulfide isomerase 
PLA: Proximity Ligation Assay 
PMSF: phenylmethane sulfonyl fluoride 
PAGE: Polyacrylamide gel electrophoresis 
PP2A: Protein Phosphatase 2A 
PP2AA: Scaffold A subunit of Protein Phosphatase 2A 
PP2AC: Catalytic subunit of Protein Phosphatase 2A 
 
RCI: Random Coil Index 
 
S1P: Sphingosine-1-phosphate 
SCR: scramble sequence 
SDS: Sodium Dodecyl Sulfate 
SET: Su(var), Enhancer-of-zeste, Trithorax 
SILAC: Stable isotope labeling of cells in culture 
shRNA: Short hairpin ribonucleic acid 
SK1: Sphingosine kinase 1 
SK2: Sphingosine kinase 2 
SPL: Sphingosine-1-phosphate lyase 
SPR: surface plasmon resonance 
SPT: Serine palmitoyltransferase 
STD-NMR: Saturation Transfer Difference Nuclear Magnetic Resonance 
TOCSY: Total Correlational Spectroscopy 
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Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase with 
tumor suppressor function. PP2A holoenzyme contains numerous combinations of its 
various isoforms of scaffolding (A), regulatory (B), and catalytic (C) subunits. In many 
cancer types, an endogenous PP2A inhibitor, inhibitor 2 of PP2A (SET) oncoprotein, is 
overexpressed, resulting in PP2A inhibition, leading to enhanced cell growth, and 
attenuation of cell death. It is known that targeting SET with bioactive sphingolipid 
ceramide or sphingolipid analogue drug FTY720 leads to the reactivation of PP2A, 
leading to necroptosis. However, structural details of the interaction between SET and 
FTY720 (or ceramide) with regards to mechanism of the PP2A activation have been 
unknown. Here, we report the first in solution examination of SET-sphingolipid complex 
by NMR spectroscopy. Data revealed that FTY720 binding may result in a structural shift 
in the N-terminal region of SET, which prevents its oligomerization. This then leads to 
the release of SET from the catalytic subunit of a specific PP2A holoenzyme, which 
comprises PP2AAβ, PP2A-B56γ, and PP2ACα subunits, for increased PP2A activity, 
while SET remains associated with the PP2A-B56γ. The activation of this specific PP2A 
holoenzyme by SET-FTY720 complex then regulates a number of downstream effector 
proteins involved in various biological functions, such as tumor suppressor non-muscle 
myosin IIA. Attenuation of FTY720-SET association by point mutations enhances SET-
PP2A inhibitory complex, leading to resistance to PP2A activation, which is recapitulated 


























Sphingolipids and Cancer 
 
Sphingolipids are a class of lipids responsible for the fluidity and creation of sub-
domains in lipid bilayers. Research over the last two decades established sphingolipids as 
bioactive molecules with roles in a variety of cell signaling processes.  Ceramide and 
sphingosine-1-phosphate (S1P), are the best characterized sphingolipids with roles in 
cancer pathogenesis. They function in cell death, cell migration, cell proliferation, 
inflammation, and senescence.  
Ceramide is the central molecule of sphingolipid metabolism (Fig. 1). It is 
composed of a sphingosine backbone that is esterified to a fatty acyl chain by an amide 
bond to carbon 3 of the sphingosine base1–3. A hallmark of biologically active ceramide, 
is the trans-double bond between carbons 4 and 5 on the sphingosine backbone2,4,5. 
Failure to produce or loss of this double bond results in the formation of dihydro-
ceramide. There is great variety in fatty acyl chain length (C14-C26), resulting in many 
different species of ceramide, each with specific cellular roles6–8. 
Ceramide can be produced through 1) de novo synthesis from the condensation of 
serine and palmitoyl-CoA, 2) the hydrolysis of sphingomyelin, or 3) the acetylation of 
sphingosine (Fig. 1). It is a potent lipid-messenger involved in regulating apoptosis, 
cancer-cell growth, senescence, and cell differentiation 6–8. Ceramide is also the building 
block for other complex sphingolipids such as sphingomyelin, glycosphingolipids, and 
gangliosides. Sphingosine-1-phosphate is another important sphingolipid in cancer 
pathophysiology. 
 S1P is catalyzed by sphingosine kinases 1 (SK1) and 2 (SK2). The substrate 
sphingosine is generated by the catabolism of ceramide by acid ceramidase (AC), where  
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Figure 1| Schematic of known sphingolipid metabolism 
Sphingolipids are built with three main groups: a sphingosine backbone, a fatty acyl 
chain, and a polar head group. Changes to either the head group or acyl chain length drive 
sub-cellular localization and function. Cells tightly regulate these pathways to maintain 
the balance between pro-proliferative sphingosine-1-phosphate and the cell death-






the fatty acyl chain is removed. SK1 and SK2 then add a phosphate group to the a-
hydroxyl of sphingosine. S1P is then secreted from cells where it can engage S1P 
receptors to initiate various signaling pathways in a paracrine or autocrine fashion. S1P 
receptors (1-5) are a family of G-protein-coupled receptors. Sphingosine-1-phosphate is 
considered a pro-survival lipid because of its involvement in inflammation, 
vasculorogenesis, metastasis, and its ability to counter apoptosis10,11.  
Most of the enzymes in the sphingolipid metabolic system have been cloned and 
characterized. Comprehensive research has defined their roles in either tumor suppression 
or pro-survival signaling. As ceramide and S1P are the central bioactive molecules of the 
sphingolipid world, dysregulation of their respective enzymatic pathways usually result 
in an imbalance of one or the other, and contributes to malignant pathologies accordingly.  
 
Sphingosine-1-Phosphate and Cancer 
  
Enzymes relating to the production and destruction of S1P have well defined roles 
in cancer. While S1P is a known pro-survival signaling molecule, the breakdown of S1P 
by sphingosine-1-phosphate lyase (SPL) leads to an accumulation of ceramide and 
subsequent cell death in colon cancer cells1–3. Cytosolic S1P, generated by SK1, initiates 
pro-survival signaling and metastasis in lung, bladder, and melanoma cell lines and 
mouse models via a number of signaling cascades12. Nuclear S1P, generated by SK2, can 
cause drug resistance by stabilizing telomerase, thus extending telomere length and cell 
survival in lung cancer cells13. It can also inhibit HDAC1 and 2 to epigenetically promote 
pro-survival signaling in breast cancer cell lines13. 
 6 
 S1P can act in both receptor-dependent and receptor-independent manners, 
although the receptor-dependent signaling is the first that comes to mind.  It seems that 
the effects of S1PR signaling are receptor and cell type dependent. For example, S1PR 
signaling is anti-proliferative in B cell and T lymphoblastic lymphomas14,15, while S1PR2 
signaling supports increased cancer cell proliferation, motility, and metastasis in AML, 
bladder, and melanoma models16–18. Interestingly, host/systemic S1P plays a role in 
tumor progression and metastasis by manipulating both immune cell and cancer cell 
functions3,16,19–21. Microfluidics chamber experiments and FACS cell sorting 
demonstrated that T-cells follow an S1P gradient for thymic egress22,23. There is evidence 
that S1PR3 signaling promotes stem cell-like characteristics in cancer cells; although the 
mechanism still remains rather ambiguous. Intriguingly, SMAD3, an important 
component in the TGFb signaling family, has been shown to activate S1PR3 in a 
metastatic lung cancer mouse model24. S1PR4 promotes cell growth of estrogen receptor 
(ER)-negative breast cancer cells by preventing nuclear translocation of S1PR2 by an 
unknown mechanism25. Expression of S1PR4 was also associated with lower survival 
rates in ER-negative breast cancer patients26. A recent study showed that S1P-S1PR5 
stimulated mitosis through a PI3K-AKT-PLK1 signaling cascade resulting in defects in 
chromosomal segregation27.  Antagonism of S1P receptors 1-5 signaling could hinder 
cancer growth and metastasis, dependent upon matching the correct receptor to the 
correct cancer type. 
 S1P is able to regulate cancer cell signaling by binding directly to protein targets 
other than the S1P receptors. SK1-generated S1P has been shown to interact with TRAF2 
and PPARg, initiating NF-kB signaling and PPARg-dependent gene expression 
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responsible for angiogenesis and metastasis28–30. Nuclear-localized S1P generated by SK2 
was found to directly bind HDAC1 and HDAC2 by mass spectrometry lipidomics 
analysis, promoting the expression of both p21 and the proto-oncogene FOS13. 
Furthermore, S1P localized to the nuclear envelope binds to and stabilizes hTERT, the 
catalytic subunit of telomerase, by mimicking phosphorylation at Ser921 12. This prevents 
ubiquitylation by MKRN1 and degradation of hTERT, leading to preservation of 
telomere integrity and senescence, both of which are hallmarks of cancer. Intriguingly, 
SK2 has been reported in mitochondria where S1P directly interacts with PHB2 to 
enhance Complex IV activity and overall mitochondrial respiration31 as measured by 
oxygen consumption rate.  
 
Ceramide and Cancer 
 
Ceramide is considered the bioactive lipid mediator of cell death. Many studies 
show that changes in the endogenous levels of ceramide in response to chemotherapeutic 
agents is a trigger for apoptosis32–36, necroptosis, endoplasmic reticulum (ER) stress/cell 
cycle arrest, and lethal mitophagy37–39 (Fig. 2). There is also evidence for roles in pro-
proliferative signaling. Each of these pathways for cell death is dependent upon tissue, 
subcellular localization of the sphingolipids, and target availability. The de novo 
synthesis of ceramide in the ER by the serine palmitoyltransferases 1-3 (SPTs) and their 
auxiliary subunits40 increases as  a response to chemotherapeutic agents and radiation 
therapy in breast cancer cells41,42. Additionally, the increased production of dihydro-
ceramides, ceramide precursors, by (dihydro) Ceramide Synthases (CERS) 1 and 6 
induces cell death in an acyl chain-dependent and tissue-dependent manner. The 
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synthesis of C18 ceramide by CERS1 causes lethal mitophagy in both AML and head and 
neck cancer cell lines38,39,43,44. CERS6, generates C16 ceramide, activating caspase-
dependent cell death in lung cancer cells. Elevated levels of CERS6 have been shown to 
be beneficial in head and neck, breast, colon, leukemia, and glioblastoma cell lines and 
mouse models45–51. To the contrary, there is also a report that describes C16 ceramide as 
having pro-survival functions45. CERS6/C16-ceramide expression protected against ER 
stress by activating the ATF6/CHOP unfolded protein response pathway. Genetic 
knockdown of CERS6/C16-ceramide resulted in ER stress and apoptotic cell death in 
head and neck squamous cell carcinomas45. Dihydro-ceramide desaturase (DES) 
produces mature ceramide by desaturating the bond between carbons 4 and 5 on the 
sphinganine backbone52. The resulting accumulation of ceramide causes cell cycle arrest 
in neuroblastoma cells. These enzymes are all part of the biosynthetic pathway of 
ceramide generation.  
Ceramide can also be generated by the catabolism of more complex sphingolipids 
or used as a substrate to make more complex sphingolipids. Neutral sphingomyelinase 
(NSMase) generates ceramide by the hydrolysis of sphingomyelin. This activity has been 
linked with cell-cycle arrest and exosome release in breast cancer cells53–55. Acid 
sphingomyelinase (ASMase) also generates ceramide by the hydrolysis of 
sphingomyelin, but research has shown dual, opposing functions such as induction of 
apoptosis in lymphoblasts, while promoting metastasis of hematogenous tumors in some 
mouse models32,56,57.  
Other ceramide-related enzymes have roles in pro-proliferative signaling. 
Ceramide transfer protein (CERT) transports ceramide from the ER to Golgi for 
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packaging and transport to the plasma membrane where the ceramide can be converted to 
sphingomyelin58,59. An increase in CERT activity can drain the bioavailability of 
ceramide and inhibit ceramide-mediated apoptotic signals in breast cancer cells and 
mouse models60–62. Acid ceramidase (AC) removes the fatty acyl chain, producing 
sphingosine as a byproduct. This has a two-pronged effect: First, it lowers the 
bioavailability of ceramide. Then the increase in sphingosine creates an increase in S1P 
as well, resulting in an imbalance between the anti- and pro-proliferative lipids63–66.  
Increased ceramide kinase (CERK) activity is able to promote cancer cell survival 
in mouse models by converting ceramide to ceramide-1-phosphate (C1P)67–69. 
Glucosylceramide synthase (GCS) activity stimulates drug resistance in patients with oral 
cancers and in mouse models of breast cancer70–74. Both enzymes discussed above work 
by  reducing ceramide levels and its anti-proliferative signaling capabilities by converting 
ceramide to a more complex sphingolipid. Similar to S1P, nuclear ceramide can also 
regulate hTERT. The repressor function of the SP3-HDAC1 complex is enhanced by 
ceramide along with the prevention of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) nuclear localization, which is known to protect telomeres75,76. 
Ceramide is able to bind directly to specific proteins targets to regulate tumor 
growth77. Ceramide activates the mitogen-activated protein kinase (MAPK) signaling 
cascade by binding to both c-Raf and kinase suppressor of RAS (KSR)34,78,79. Likewise, 
ceramide binds to and activates PKC-z, which is a kinase well known to be involved in 
cell survival. However, the lipid-protein complex is then targeted to stress-activated 
protein kinase (SAPK), resulting in tumor suppression80. Cathepsin D contributes to 
metastasis and tumor growth by degrading extracellular matrix proteins. When bound by 
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ceramide, cathepsin D induces self-proteolysis and apoptosis81. Another major ceramide-
binding protein is Inhibitor 2 of Protein Phosphatase 2A (I2PP2A or SET), which will be 
discussed later in the chapter.  
 
 
Figure 2| Ceramide signaling and cancer cell death pathways 
Ceramide accumulates in response to various stressors, such as chemotherapies and radiation, to 
trigger cell death through direct and indirect targets. The ceramide is generated de novo, by the 
hydrolysis of sphingomyelin, or scavenged and transported from late endosomal organelles. 
Ultimately the localization and fatty acyl chain length dictate the manner of cell death. C16 or 
C18 ceramides localized to the mitochondria initiate apoptosis or mitophagy, respectively. C18 
ceramide generated in the ER can activate tumor PP2A through direct binding to SET to initiate 
necroptosis or can accumulate in the ER and trigger autophagy or apoptosis depending on the 






Sphingolipids as Cancer Therapies 
  
In the previous section, we discussed roles for sphingolipids and their enzymes in 
cancer progression and tumor suppression. Dysregulation of these enzymes within the 
sphingolipid biosynthetic pathway can cause an imbalance between anti-proliferative 
ceramide and pro-proliferative S1P, leading to cancer pathologies (Fig. 3). Sphingolipid-
based therapeutics are designed to shift the balance in favor of ceramide to induce a 
variety of cell death mechanisms. Table 1 lists anti-cancer drugs that target sphingolipid 
metabolism. These potential therapeutics can be divided into two main categories: 
Ceramide analogs/producers or inhibitors of S1P signaling/production. 
Ceramide analogs are an interesting therapeutic avenue. The problem of delivery 
has always been an issue due to solubility problems with the long fatty acyl chains of 
ceramides. Pyridinium-conjugated ceramides have circumvented this problem by 
increasing water solubility and membrane permeability of long chain ceramide analogs. 
Interestingly, the positive charge of the pyridinium ring cause the ceramides to 
accumulate in the mitochondria of cancer cells, inducing lethal mitophagy37–39,82. Other 
cationic, short-chain ceramides have been very effective at inducing apoptosis in a 
variety of drug-resistant breast cancer cell lines83,84. Ceramide delivery via 
nanoliposomes has been very effective in the preclinical stages and is now advancing to 
Phase I clinical trials for the treatment of patients with advanced stage solid tumors85–88.  
Halting the generation of S1P by targeting sphingosine kinase 1 and 2 is also 
being pursued as an anti-cancer strategy. SK1-I is a competitive inhibitor of SK1 and has 






Figure 3| Balance of Ceramide and Sphingosine-1-phosphate in cancer pathology. 
In many cancers a decrease in ceramide is observed along with a corresponding increase 
with S1P. This results in an imbalance that favors cell proliferation, metastasis, and drug 
resistance. Sphingolipid-based therapeutics are designed to shift the balance in favor of 
ceramide to induce a variety of cell death mechanisms. (Taken from Ponnusamy et al. 




PF-543 is another SK1 inhibitor in development. Initially thought to be ineffective, 
further studies have shown inhibition of cell propagation in colorectal cancer and triple 
negative breast cancer cell lines and mouse models90–92. There is also an inhibitor for 
SK2, ABC294640, which has is currently in a number of Phase I and Ib clinical trials93,94. 
It has completed a Phase I trial against solid tumors and is now in a Phase II clinical trial 




TABLE 1: Drugs that Target Sphingolipid Metabolism 






CHC CERT/inhibits ceramide 





NVP-231 Ceramide kinase Preclinical 68 
LCL521 and 
LCL204 


















JTE013 S1PR2 Preclinical 16 
AB1 S1PR2 Preclinical 102 
SK1-I SK1 Preclinical 89 
PF543 SK1 Preclinical 90–92 
VPC03090 S1PR1;S1PR3 Preclinical 103 
Sphingomab 
(sonepcizumab) 
S1P Phase II 104 
ABC294640 SK2; DES Phase Ib and II 93,94,105–110 
*Table adapted from Ogretmen. Nature Reviews. 2017 
 
 
There is also an anti-S1P antibody20, Sphingomab, which recently completed a Phase II 
clinical trial against renal clear cell carcinoma104. The efficacy was weak, however, 
suggesting that the antibody alone may not be enough. Perhaps in concert with an SK1 or 
SK2 inhibitor, patients may respond better. More studies are needed to understand the 




Protein Phosphatase 2A 
 
Protein Phosphatase 2A (PP2A) is a member of the protein phosphatase family 
(PPP) and the serine/threonine phosphatase super family. A major regulator in both cell 
division and apoptosis 111–113, the PP2A holoenzyme consists of three unique subunits. 
The ‘Core Enzyme’ is comprised of a 36 kDa catalytic ‘C’ subunit (PP2AC) and a 65 
kDa scaffolding ‘A’ subunit (PP2AA). The third subunit is a regulatory ‘B’ subunit 
(PP2AB). There are 18 known B subunit isomers, each conferring unique substrate and 
tissue specificity to PP2A, accounting for its variety of functions in multiple cellular 
processes. This heterogeneity has led to the mapping of trimeric holoenzyme PP2A 
complexes to almost 300 protein targets ranging across myriad biological functions 114.  
Table 2 gives a full listing of PP2A subunits and their subcellular localization. Given the 
number of subunits, there are 72 unique PP2A holoenzymes, each with its own set of 













TABLE 2: PP2A Subunit Names and Subcellular Localization 
Subunit Gene 
Name 













































PR61b, B56b, R61b2 
PR61g1, B56g1, B'a3 
























None PR110, PR93 












*Adapted from Chen et al. Gastroenterology Research and Practice 2013. 
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The catalytic PP2AC has two forms (a and b) that are encoded by two separate 
genes with 97% DNA sequence similarity. PP2ACa is the predominant catalytic subunit 
in cells. Despite their similarity, one subunit cannot compensate for the other because of 
their differences in expression. The scaffolding A-subunit is the platform for the 
assembly of the holoenzyme. It binds to the C-subunit with its N-terminus and to the B-
subunit with its C-terminus via tandem-repeat regions known as HEAT 
(huntingtin/elongation/A subunit/TOR) motifs (Fig 4). The HEAT repeats create a 
horseshoe-shaped structure that orients the C and B subunits to the same side of the A 
subunit 115 (Fig. 4). This precise orientation is essential for substrate recognition and 
activity. The A subunit also has two forms (a and b), with 87% DNA sequence 
similarity. Aa is ubiquitously expressed, but Ab expression varies by tissue. Similar to 
the C subunit, the A subunits are unique and one cannot compensate for the loss of the 
other 116. Mutations in either Aa or Ab, found in some cancers at low frequencies, cause 
a disruption in the assembly of the PP2A holoenzyme and compromise PP2A-mediated 
















Figure 4| Assembly of the PP2A holoenzyme onto the A subunit. 
The HEAT repeats of the A subunit create a horseshoe-shaped structure that orients the C 
and B subunits to the same side of the A subunit. The bottom panel details a single helix-
turn-helix repeat is shown in the center, with the outer helix in pink, the inner helix in 
green, and the turn in white. (PDB ID 2IAE. Cho US, Xu W. Crystal structure of a 





The regulatory B subunits are the most varied, comprising of four unique gene 
families: B, B', B'', and B'''. Each member of the four families has minimal overall 
sequence similarity 111. This variety in the B-subunits accounts for the functional 
specificity of PP2A 121–128. The B family is made up of four isoforms: a, b, g, and d. The 
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a and d isoforms are ubiquitously expressed, while g and b are predominantly expressed 
in the brain 111. The B' family is comprised of five isoforms: a,b,g, d, and e, each with 
multiple splice variants. Their expression also varies by tissue and subcellular 
localization. All B' family members contain a centrally conserved region that is required 
for A and C subunit interaction. They are dissimilar in both the N- and C-termini, 
possibly conferring different functions and substrate specificities 121. B'56g in particular 
has been found to be important in tumor suppression, and various mutations or changes in 
expression can disrupt this function 129–131. The B'' family also has five isoforms; they 
differ from the other families in that they are splice variants of the same gene.  The B''' 
family is the most recently discovered and has been found predominantly in neuronal 
cells 132. Alterations in some B subunits have been found in certain cancers 132–135.  
Post-translational modifications are a major regulator of the phosphatase activity 
of the catalytic subunit. PP2AC activity is strictly controlled by phosphorylation at 
threonine (Thr) 304 and tyrosine (Tyr) 307. Autophosphorylation-activated protein kinase 
phosphorylates at Thr304 136,137. Tyr307 can be phosphorylated by various receptor and non-
receptor tyrosine kinases and is typically a sign of reduced activity 138,139. Methylation at 
leucine 309 is thought to be a precursor to assembly of the holoenzyme and activation 138. 
Interestingly, some reports show that C18-ceramide can enhance methylation in vitro 
through an unknown mechanism 140,141. In addition to post-translational modifications, 







Ceramide and FTY720 
 
The balancing act between the lipid-messengers ceramide and sphingosine-1-
phosphate in cancer progression provide an appealing area for drug development. Great 
strides have been made in developing 
some promising anti-cancer therapies, as 
discussed in the previous section. An 
area of drug development where little is 
currently being done, but with huge 
potential, is the activation of tumor 
suppressive Protein Phosphatase 2A. 
Ceramide (Fig. 5) has long been known 
to activate PP2A 142. Ceramide is also a 
known ligand of PP1A, leading to the 
dephosphorylation of RB and growth arrest in cancer cells143,144. The generation of 
proapoptotic variants of caspase 9 and Bcl-x in lung cancer cells is also PP1A-ceramide 
dependent143. However, whether ceramide actually activates PP1A is still unclear.  
Similarly to ceramide, it was  shown that pro-drug FTY720 (Fig. 5) activated PP2A, 
resulting in cell cycle arrest, apoptosis, or necroptosis 97,145. FY720 (fingolimod, Gleevec) 
is a sphingosine analog approved by the FDA for the treatment of multiple sclerosis146. 
This pro-drug is phosphorylated by sphingosine kinase 2, and exported from the cell, 
where it targets the sphingosine-1-phosphate receptor 1 in an autocrine/paracrine 
manner147. The subsequent internalization and degradation of the receptor leads to 
immune suppression. Since then, many groups have reported that ceramide and FTY720 
Figure 5| Chemical structures of D-e-C18 
ceramide and  FTY720  
Both molecules have polar head group 
consisting of two hydroxyls and an amine. 
Both also have long saturated hydrocarbon 
tails. FTY720 has an aromatic ring instead 
of a fatty acyl chain. 
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activate PP2A 97,148–150 by targeting an endogenous protein inhibitor, and that the 
reactivation of PP2A, in general, has potent tumor suppressive powers. 
 
 
Inhibitor 1 of PP2A 
  
I1PP2A (also known as acidic leucine-rich phosphoprotein 32 A or ANP32A or 
PHAP1 -Putative HLA-DR-associated protein 1) is a sphingosine/dimethyl sphingosine-
sensitive PP2A inhibitor found in human umbilical vein endothelial cells (HUVEC)151,152. 
Sphingosine binding to I1PP2A increases PP2A activity and leads to the expression of 
COX2, a major mediator of inflammation152. I1PP2A also plays a role in the histone 
acetyltransferase INHAT complex. Another member of the ANP32 family, ANP32e, is a 
PP2A inhibitor with a role in neuronal development153,154. Its role in cancer progression is 
defined by the type of cancer being studied. In non-small cell lung, breast and pancreatic 
cancers, I1PP2A has been described as a tumor suppressor154–156. However, I1PP2A 
expression in glioma, prostate, colorectal, hepatocellular carcinoma, and oral squamous 
cell carcinoma promotes cancer cell progression157–162. Interestingly, I1PP2A may have a 
more important role in neurodegenerative disorders such as Alzheimer’s Disease. 
Deficiency in PP2A activity leads to a hyperphosphorylation of tau protein, a component 
neurofibrillary plaques, and cognitive impairment in rat models163–165.  
 
 
Cancerous Inhibitor of PP2A 
 
CIP2A is a 90 kDa protein with no significant homology to any protein with a 
known function. It does, however, have a number of protein binding domains166–168. It is 
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known as the c-Myc protector, by preventing the dephosphorylation of S62 and 
promoting c-Myc stability169. In addition to c-Myc, CIP2A protects other PP2A-targeted 
proteins such as E2F1, Akt, DAPK1 (death-associated protein kinase 1), and Plk1 (polo-
like kinase 1)170. CIP2A was first detected in a leukemia patient and has subsequently 
been described to have both proto-oncogenic and prognostic value in cancers171. 
Expression is localized primarily to the cytoplasm of cancer cells, whereas expression is 
non-existent in non-transformed cells172. Interestingly, CIP2A-negative tumors respond 
better to treatment than CIP2A positive tumors173. Because of this, CIP2A overexpression 
can be associated with tumor stage and as a prognostic marker for survival174. There are a 
number of potential therapeutics in the preclinical stages of development being tested in 
many cancer types. Only Celastrol has progressed beyond the preclinical stages175. 
Celastrol enhances CIP2A/CHIP interaction, leading to ubiquitination and degradation. 
Specificity and overall toxicity have been issues in drug development because of CIP2A 
direct regulation of oncogenic transcription factors such as E2F1 and c-Myc. Targeting 
CIP2A could be a promising avenue for cancer therapy, but is there a better option to 
reactivate tumor suppressive PP2A? 
 
 
Inhibitor 2 of PP2A 
 
One of the most studied and still enigmatic endogenous PP2A inhibitors is 
Inhibitor 2 of PP2A (I2PP2A/SET also known as TAF-1b). SET belongs to a family of 
SET domain-containing acidic proteins that tend to be nuclear. First identified in 
Dosophila melanogaster, SET (Su(var), Enhancer-of-zeste, Trithorax) domain-containing 
proteins play a role in gene transcription and histone methylation176. SET was originally 
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observed as a chimeric protein in a single acute lymphocytic leukemia (ALL) patient 
sample 177,178 by a fusion between full length SET with the C-terminal end of CAN 
nuclear pore protein. SET is predominantly nuclear, with functions in the histone 
acetyltransferase regulatory INHAT complex151 in addition to its inhibitory role of PP2A 
regulation. SET can also form an inhibitory complex with nm23-H1 to mute metastasis 
179. Structurally, SET (37kDa) has several domains, each with specific functions. A 
region between residues 36-124 near the N-terminus is critical for PP2A inhibition180. 
The C-terminal end has a highly acidic stretch of glutamic and aspartic acids, which is 
crucial for histone binding181. The coil-coiled domain (E25-Q65) controls SET 
dimerization, which partially controls the nuclear functions of SET182. It is thought that 
SET directly inhibits PP2A by binding the C-subunit, but details on the interaction 
between SET and PP2A have not been described. 
Along with being a potent PP2A inhibitor, SET is also a well-described proto-
oncoprotein. Chromosomal mutations of the SET gene have been associated with acute 
myelogenous leukemia183. SET is involved in a variety of cancers through 
phosphorylation changes 98,184–187, overexpression 184,188–190, and loss of inhibitory 
ceramide 191. There has been some in vitro evidence showing ceramide directly activates 
PP2AC 149,150, but the predominant mechanism of ceramide-induced activation of PP2A 
is through direct binding of ceramide to SET 97,148,192,193. Previous research identified 
SET as a binding partner with ceramide 148. SET has a high affinity for D-erythro-C18-
ceramide 97,148, with only minimal specificity for other acyl chain length ceramides. 
Subsequent studies showed that FTY720 and not P-FTY720 binds to SET with a 
comparable affinity to C18-ceramide97.  
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 Structural modeling of FTY720 and C18-ceramide binding was completed using 
a partial SET crystal structure. Sequence alignment suggests that SET has a hydrophobic 
binding pocket similar to that of the ceramide-binding domain of CERT, a ceramide 
transport protein 97. The current in silico model supports the presence of this hydrophobic 
pocket in SET containing lysine 209 and tyrosine 122. We believe these residues create a 
gating mechanism with their side chains. In this potential mechanism, the cationic ε-
amino group of lysine would participate in hydrogen bonding with the π-system of the 
aromatic ring of tyrosine. Mutation of lysine 209 to aspartic acid would “close” the gate 
and reduce SET/ceramide binding compared to wild type (WT), while a tyrosine 122 to 
cysteine mutation would enhance SET/ceramide binding by “opening” the lipid- binding 
gate.  
 
 SET-Targeted PP2A Activation in Cancer Treatment 
  
 The tumor suppressive function of PP2A was first noted almost 30 years ago 
when known carcinogen okadaic acid was found to specifically inhibit PP2A 194–196. 
Since then, PP2A activity has been found to be inhibited in multiple cancers 97,98,188,197, 
and the reactivation of PP2A induces cell death in these cancer cells. Overexpression of 
various endogenous protein inhibitors such as SET inhibits the tumor suppressive activity 
of PP2A. Furthermore, chromosomal mutations of the SET gene are associated with 




incidence of overexpression in many cancers, resulting in poor clinical outcomes198,207. 
The therapeutic value of targeting SET to reactivate tumor suppressor PP2A has 
been shown in many cancer cells. 
Genetically targeting SET in Chronic 
Myeloid Leukemia (CML) cell lines 
resulted in reduced BCR/ABL activity 
and apoptosis 188. Targeting SET with 
shRNA or the synthetic peptide inhibitor 
OP449 208 reactivates PP2A and induces 
cell death in B-Cell Chronic Lymphocytic 
Leukemia cells (B-CLL) 202,209. Recently, 
targeting SET with OP449 was shown to 
sensitize drug-resistant myeloid leukemia cells (AML and CML) to tyrosine kinase 
inhibitors (TKIs) 201,209. In addition, targeting SET demonstrated curtailed tumor growth 
in breast cancer cell lines, resulting in PP2A activation and reduced c-MYC 
stability/activity 206. Recently, it was shown that FTY720 causes a significant increase in 
ceramide levels in the M2 subtype of acute myeloid leukemia (AML-M2). The resulting 
activation of PP2A is thought to be through SET inhibition and subsequent apoptosis 199. 
It is interesting to note that the pro-drug FTY720 and not phospho-FTY720, have the 
SET-targeting anti-cancer functions. Lipidomics analysis showed that pro-drug FTY720 
accumulated predominantly in lung tumor tissues, while phospho-FTY720 was found in 
serum of mice after treatment97.  
 
TABLE 1: Types of Cancer with SET 
Overexpression 






Lung adenocarcinoma 97,148 






Hepatocellular carcinoma 205 
Breast cancer 206 




Although the therapeutic value of targeting SET to reactivate PP2A is well 
documented in many cancer types, little is known about its interactions with the tumor 
suppressor PP2A. The structural details of the interaction between SET and FTY720 (or 
ceramide) with regards to mechanism of the PP2A activation are also unknown. In this 
study, we seek to define the interplay between SET and PP2A, with particular attention to 
its regulation by ceramide and FTY720. The structural information obtained concerning 
the lipid-binding pocket of SET will provide the foundation for the development of 
FTY720/ceramide analogs as novel SET inhibitors to reactivate tumor suppressor PP2A 
with improved specificity and anti-cancer function, without immune suppression and 




























The various SET genes were cloned into pET-22b (+), pET-28b (+), or pHGK vectors. 
BL21 pLys cells were transformed and grown in four liters of Luria-Bertani (LB) media 
at 37°C with 100µg/ml ampicillin or kanamycin. Protein expression was induced with 
0.05 mM IPTG for three hours, with shaking at 225rpm. The cells were collected, lysed 
by sonication, and the lysate was then clarified by centrifugation. The protein was loaded 
onto a sepharose Fast Flow HisTrap column (GE Healthcare) and eluted with 200 mM 
imidazole. The elution fractions were then pooled and loaded onto a HiLoad 16/60 
Superdex 200 prep grade column. The pooled fractions were then dialyzed overnight at 
4°C into phosphate buffer (20 mM phosphate buffer, 50 mM NaCl pH 8.0).  
(*Detailed protocols of purification and recipes for isotopically-labeled proteins can be 
found in Appendix I).  
 
Backbone Assignment of SET by NMR 
The backbone of 13C/15N/2H-labeled Nd-SET was assigned using standard triple 
resonance experiments 210–217. Experiments were acquired in 20 mM phosphate buffer, 50 
mM sodium chloride pH 8.0 and 1% D20 at 310K on a Bruker Ascend 850 MHz 
spectrometer using a 5mm cryogenically cooled triple resonance z-gradient probe. Data 
were processed in TopSpin (Bruker BioSpin) and spectral analysis was done in 






















TRHNCACB 13C-15N-2H 128 128 2048 214,217 
TRCBCACONH 13C-15N-2H 128 128 2048 212 
TRHNCA 13C-15N-2H 200 256 4096 219 
TRHNCOCA 13C-15N-2H 256 256 256 210 
TRNHCO 13C-15N-2H 256 128 4096 211,213,216 




Experiments were acquired in 20 mM phosphate buffer, 50 mM sodium chloride pH 8.0 
and 5% D20 at 310K on a Bruker Ascend 850 MHz spectrometer using a 5mm 
cryogenically cooled triple resonance z-gradient probe. For the NMR titration analysis, 
Nd-Cd SET was incubated with 0.5 µM-10.0 µM FTY720, D-e-C18 ceramide, or L-e-
C18 ceramide in 0.5 µM increments. Chemical shift perturbations were monitored using 
BEST-TROSY experiment 222–224. Data were processed in TopSpin (Bruker BioSpin) and 
spectral analysis was done in CCPnmr2.2.2218. Chemical shift perturbations were 










Structural Identification of FTY720 and D-e-C6-pyridinium ceramide protons 
The following two-dimensional experiments were collected on a Bruker Avance II 
600MHz spectrometer using a 5mm cryogenically cooled quadruple resonance QCI probe 
at a temperature of 298K.  
 
TABLE 3: Two-Dimensional NMR Experiments 










Dq-COSY 1H-1H 512 2048 16 none 226 
HSQC 1H-13C 256 2048 16 none 227 
HMBC 1H-13C 256 2048 16 none 228 
NOESY 1H-1H 256 2048 16 0.5s, 0.3s 229 
 
 
Saturation Transfer Difference NMR 
All STD-NMR experiments were carried out on a Bruker Avance II 600MHz 
spectrometer using a 5mm cryogenically cooled quadruple resonance QCI probe at a 
temperature of 298K. A pseudo-2D version of the STD NMR sequence was used for the 
acquisition of on- and off-resonance spectra 230–232. For selective saturation, cascades of 
Gaussian pulses were used with a pulse length of 50 ms and 41.9 dB. The on-resonance 
frequency was set to 0.034 ppm to saturate methyl resonances 233 and the off-resonance 
frequency was set to -25.0 ppm for all experiments. To obtain the STD buildup curves 
saturation times were 0.1, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, and 
6.0 seconds. Eight scans were used with each experiment. LCL29 titration concentrations 
were 0.1, 0.2, 0.3, 0.4 and 0.5 mM with the protein concentration of 50 µM. For each 
titration, a STD buildup curve was recorded. For analysis a STD amplification factor 
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(STD-AF) is used to assess the absolute magnitude of the saturation transfer difference 
234. This factor is the partial saturation of a specific proton multiplied by the excess 
concentration of ligand. It is calculated as: STD-AF= (Io – Isat)/ Io • [ligand excess] where 
Io is the reference spectrum and Isat is the saturation spectrum. 
 
Diffusion-Ordered Spectroscopy (DOSY) 
Experiments were performed on a 400MHz Oxford spectrometer with a broadband probe 
at 295K. 32 scans were collected through a linear gradient with a 1.25s delay (D1), D = 
0.1s, and d =2500 µs. 
 
Molecular Modeling of SET with Ceramide or FTY720 
Modeling and simulations were performed using MOE 2018 (Chemical Computing 
Group, Inc). Structural PDB was SET:pdb2E50 (PMID 17360516)235. Before simulations 
the monomer was isolated and protonated at T=310K, pH 7.3, salt at 200mM using 
GB/VI electrostatics.  Docking simulations used induced fit for the receptor and flexed 
the ligand.  For each docking simulation, initial placement calculated 50 poses using 
triangle matching with London ∆G scoring, then the top 30 poses were refined using 
forcefield (Amber10: ETH) and Affinity ∆G scoring (Escore2).  The top 10 poses from 
these simulations were analyzed and the top scoring pose is presented.  For FTY720 we 
used the final model generated from our previous paper (PMID 23180565)97 but allowed 
induced fit of the receptor.  For C18 ceramide, we performed two iterative induced fit 
docking simulations.  The first simulation allowed access to the entire protein; the second 
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round used the top pose from the first round and used the ligand atoms as the site to be 
probed. 
 
Cell lines and Reagents 
A549 human lung adenocarcinoma cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) (Corning) containing 10% FBS (Atlanta Biologicals) and 5% 
penicillin/streptomycin (Corning) at 37°C and 5% CO2. Overexpression vectors of WT, 
S9A, S9E, S24A, S25E, S93A, S93E, Y133F, Y133E, S171A, S171E Flag-SET were 
generated in pCDH plasmid. SET was originally cloned into MigR1 at Ecor1 and Hpa1. 
It was removed using Ecor1 and Xho1 and sub-cloned into pCDH-CMV-MCS-EF1-
copGFP (CD511B-1) via blunting the Xho1 site of FLAG-SET. The Xba1 site of pCDH 
was cut and blunted, followed by sticky-end ligation of ECOR1 sites. All stable 
knockdowns are shRNA to coding sequence unless otherwise noted: shSET/PLKO 
(3’UTR), shPP2ACα/PLKO, shPP2ACβ/PLKO, shPP2A B56δ/PLKO, shPP2A 
B56γ/PLKO (shRNA sequences can be found in Appendix I). All cell lines were 
established in A549 cells. Cells were treated with FTY720 (Cayman Chemical 
Company), D-e-C18 ceramide, L-e-C18 ceramide, D-e-C6-pyridinium ceramide 
(Lipidomics Shared Resource Facility, MUSC), and OP449 for experiments. 
 
Proximity Ligation Assay 
A549 cells were plated in each chamber of a glass four-well chamber slide and incubated 
overnight in DMEM, at 37°C, and 5% CO2. Cells were then treated with 5 µM FTY720 
or DMSO for 3 hours, washed in cold PBS, and fixed using 4% paraformaldehyde. The 
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proximity ligation assay protocol was followed as outlined by Olink Biosciecnces® 
(Sigma). Images were collected as Z-stacks on an Olympus VF10i laser scanning 
confocal microscope.   
 
Preparation and Assembly of PP2A Holoenzyme 
 All constructs and point mutations were generated using a standard PCR-based cloning 
strategy. B56ɣ1 was overexpressed in E. coli as a fusion protein with glutathione S transferase 
(GST) and purified as described 236. The PP2A core enzyme, involving the full-length Ca 
(residues 1–309) and Aa (residues 8–589), was assembled as described 236. The PP2A core 
enzyme was methylated by a PP2A-specific leucine carboxyl methyltransferase (LCMT). 
Following complete methylation, the fully methylated PP2A core enzyme was incubated with a 
stoichiometric amount of B56ɣ1. The PP2A holoenzyme was purified to homogeneity by gel-
filtration chromatography. In addition, the purified full length Ca was used to generate a carboxy-
terminally truncated variant (residues 1–294) through trypsin digestion.  
 
GST-Mediated in vitro pull-down assays 
 Approximately 20 µg of GST-holoenzyme, GST-core enzyme (PP2AA and PP2AC), or 
GST- B56ɣ1237 were immobilized onto glutathione resin (GS4B). 10 µM SET was pre-incubated 
with different concentrations of FTY720 for 30 min. SET and the holoenzyme were then mixed 
and incubated for 15-30 minutes. The resin was then washed two times with 1X TBST. The 
remaining protein and resin were mixed with 30 µl of loading buffer, heated for five minutes at 
98°C, and applied to SDS-PAGE for electrophoresis. The results were visualized by Coomassie 




Stable Isotope Labeling of Cells in Culture (SILAC) 
A549 cells stably overexpressing HA-tagged PP2ACα were grown in heavy (15N-
arginine labeled) and light (normal) DMEM media. After three weeks of growing cells, 
the ‘heavy cells’ were treated with a high dose (20 µM) of FTY720 for 2 hours, washed, 
collected, and lysed. PP2ACα was immuno-precipitated by the HA-tag in both treated 
and control cells. The elution of control and treated samples were mixed and run on SDS- 
PAGE. The gel was then Coomassie stained for analysis by mass spectrometry. The ratio 
of 15N:14N was analyzed for changes in protein levels as result of exposure to FTY720. 
 
Isothermal Titration Calorimetry 
To determine the KD value of C6-pyridinium-ceramide binding to N22d-SET, 0.05 mM 
C6-D-e-pyridinium-ceramide was injected in 1.5µl increments at 20°C into a 300 µl 
detection cell volume of 0.021 mM protein for 33 injections. As a control 0.05 mM C6-
D-e-pyridinium-ceramide was injected in 1.5µl increments at 20°C into a 300 µl detection 
cell containing 20 mM phosphate buffer, 50 mM NaCl pH 8.0. This data set was then 
used to subtract background heat changes as a result of ligand dilution.  
 
PP2A Activity Assay 
Protein lysate (100µg) was used for PP2AC immunoprecipitation with a phosphatase kit 
(Millipore), as described by the manufacturer with the exception of using purified rabbit 








All data are presented as means ± S.D. or S.E.M, and group comparisons were performed 
with a two-tailed Student’s t test. For comparison among groups with one or more 
characteristics, one-way or two-way ANOVA followed by Tukey multiple comparison 
post-hoc test was used. Analyses were performed using GraphPad Prism 7 software and p 











Chapter 3: NMR Backbone Assignments of 













To analyze the effect of lipid binding on SET structure, we first had to assign the 
backbone amide resonances of SET. In order to do this, it, was necessary to purify 
isotopically labeled protein with NMR active nuclei such as 13C, 15N, and 2H. NMR 
active nuclei possess a property called ‘spin’, meaning a charged nucleus spins about an 
axis to generate its own dipole moment. This property is necessary for NMR experiments 
because it allows nuclei to align to an external magnetic field and absorb radiofrequency 
radiation. 13C NMR active nucleus allows us to monitor the couplings between the HN, N, 
and Ca. The incorporation of 13C and 15N means that most of the NMR active nuclei 
within a given protein are separated by a single bond coupling. The [1H-15N] bond 
coupling is present in every peptide bond (except proline) and is therefore the starting 
point for heteronuclear NMR analysis (Fig. 6). Additionally, substitution of protons with 
deuterons plays an important role in the backbone assignment of large proteins. Large 
proteins (>25 kDa) are less NMR compatible due to their slower tumbling, which leads to 
unfavorable (fast) relaxation properties and deterioration of spectral quality. By removing 
the side chain protons and replacing them with deuterons, hydrogen exchange between 
protein and buffer is limited, which, in turn, improves relaxation properties and spectral 
quality238 .  
These nuclei also possess a property known as relaxation, which can pose a 
problem when collecting data on large proteins. In general, relaxation refers to the 
weakening of signal over time. This is a result of magnetized, or excited nuclei, returning 
to an equilibrium state within the external field of the spectrometer (commonly oriented 
along the z axis)238. The restoration of magnetic moments back to the bulk magnetization 
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or z-magnetization can be described by two separate processes that govern NMR signal 
decay.  
The overall process of the  z-magnetization returning to equilibrium is referred to 
longitudinal or T1 relaxation. T1 relaxation is responsible for the loss of signal intensity. 
In order to acquire data these spins need to be energized by radio frequency pulses to 
rotate them 90° away from the z-magnetization and into the transverse plane. In order to 
for the z-magnetization to return to equilibrium energy needs to be lost. This loss is 
characterized by the flow of energy between localized fields and molecular motion, 
which causes these fields to clash. This process is referred to as spin-lattice relaxation, 
where ‘lattice’ refers to neighboring molecules of the solution and the wall of the NMR 
tube itself238. Similarly, the process by which transverse-magnetization returns to 
equilibrium is called transverse relaxation or T2 relaxation. Radio frequency pulses to 
rotate NMR active nuclei 90° away from the z-magnetization and into the transverse 
plane. A small proportion of spins are bunched together in phase, a phenomenon known 
as phase coherence. As a function of time, the nuclear spins that are bunched together 
will lose their phase coherence and ‘fan out’. This can be thought of as a process of 
entropy and results in the broadening of signal238,240.  
The equilibrium state, or bulk magnetization of the sample, is dependent upon the 
number of spins, their gyromagnetic ratios, and the strength of the applied field. Each 
proton can be thought of as a bar magnet (dipole) with its own magnetic moment. The 
spinning of electrons about a nucleus as a result of a strong external field creates a 
localized magnetic field. An additional mechanism of relaxation is to as a dipole-dipole 
mechanism. Simply, there are two spins (dipoles): one generates a field and the other 
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experiences it. This mechanism is typically experienced over short distances (< 5	Å), but 
it is important to note, especially for proteins, that local fields can be contributed by 
multiple spins; therefore relaxation can be influenced by a single spin nearby or by many 
spins farther away240. 
To combat deleterious relaxation properties we engineered a double truncation 
SET construct (NdCd SET) where 52 C-terminal residues (consisting of a long 
unstructured acidic tail) were deleted in addition to the 22 N-terminal residues (Fig. 7). 
The size of the protein is more amenable to NMR spectroscopy, while still containing the 
putative lipid-binding pocket97. Additionally, NdCd SET was triple labeled with [2H-13C-
15H] by perdeuteration (See Appendix I for details on isotopic labeling and purification) 
to further enhance signal to noise. In order to assign the backbone of NdCd SET, the 
protein was triple labeled with [2H-13C-15H]. ). Substitution of protons with deuterons 










Figure 6| [1H-15N] TROSY of NdCd SET 
A Transverse Relaxation Optimized Spectroscopy shows the [1H-15N] correlation for the 
backbone amides of NdCd SET. Each peak corresponds to an amino acid, providing a 















































Figure 7| Schematic showing different truncated SET constructs used during 
backbone assignments 
Each truncated SET was designed to overlap by 30-40 amino acids. The truncation sites 
(in green) were designed to fall within regions of random coil, so as to preserve 
secondary structure. The highly acid tail of SET, residues 231-277, was built onto the 
crystal structure (PDB 2e50) to show a complete representation of how SET was 
truncated to preserve secondary structure.  
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Large proteins (>25 kDa) are less NMR compatible due to slower tumbling that 
causes unfavorable relaxation properties and deterioration of spectral quality. By 
removing most of the side chain protons, hydrogen exchange between protein and buffer 
is limited, which improves relaxation properties of the protein239. Additionally, The 13C 
NMR active nucleus allows us to monitor the couplings between the HN, N and Ca of a 
single residue via triple resonance experiments. This essentially makes the entire protein 
a connected spin system. The incorporation of both 13C and 15N means that almost all of 
the NMR active nuclei in the protein are separated by a single bond coupling. The [1H-
15N] bond coupling is present in every peptide bond (except prolines) and is therefore the 
starting point for heteronuclear NMR analysis (Fig. 7). A series of triple resonance 
experiments were then performed to assign the amide backbone of SET.  
Triple resonance experiments record the couplings between HN, N, and Ca or Cb  
The HNCACB experiment records 15N, Ca, and Cb couplings in one residue (i). It is 
paired with the CBCA(CO)NH, which records 15N, Ca, and Cb couplings in one residue 
(i) and the 13C- Ca and Cb of the preceding residue (i-1). The spectra are overlaid and the 
chemical shifts that superimpose are from the preceding ‘i-1’ residue. That residue can 
then be found as an ‘i’ by navigating to identical chemical shifts in the HNCACB. 
Sequential assignments can be connected (black lines) working from C-terminus to N-
terminus (Fig. 8). For example, in strip 1 of figure 8, the HNCACB (red and blue peaks) 
has 4 peaks in total (two red and two blue). Two peaks (one red and one blue) overlay 
with the green peaks of the CBCA(CO)NH, these are the ‘i-1’. The remaining red and 
blue peaks are the Ca and Cb of the ‘i’ residue, respectively. The Ca (blue) has a chemical 
shift around 59 ppm and Cb (red) has a chemical shift around 30 ppm, indicating the ‘i’ as 
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a valine. Navigating to strip 2 using the chemical shifts of the green peaks of the 
CBCA(CO)NH (these are the ‘i-1’) from strip 1 allows us to identify the next residue. 
The Ca (green overlaid on blue peak) has a chemical shift around 53.5 ppm and Cb (green 
overlaid on red peak) has a chemical shift around 27.5 ppm indicating a glutamate in strip 
two. The process is repeated until a unique sequence can be identified. This resulted in a 
partially assigned NdCd SET because there is still a lack of peak dispersion in the area 
between 7.8 - 8.5 1H ppm and 120 -125 15N ppm due to similar chemical shifts, which 
confers a degree of ambiguity, making assignments difficult (Fig. 9). An alternative 
































Figure 8| Triple resonance example demonstrating the 'i' and 'i-1' concept. 
[1H-15N-13C] HNCACB (red and blue) and CBCACONH (green) experiments overlaid 
for backbone assignments of NdCd SET. Data collected on 1mM protein. Red peaks 
represent Cb while blue peaks represent Ca of the ‘i’ and ‘i-1’residues. The green peaks 
represent the Ca and Cb of the ‘i-1’ residue. The spectra are overlaid and peaks in the 
HNCACB that superimpose with peaks in the CBCACONH correspond to the preceding 
‘i-1’ residue. That residue can then be found as an ‘i’ by navigating to identical chemical 
shifts in the HNCACB. Sequential assignments can be connected (black lines) working 










































hncacb = i 
cbcaconh = i-1 






Figure 9| Partially assigned NdCd SET after [2H-13C-15H] triple resonance 
experiments. 
The region between 7.8 - 8.5 1H ppm and 120 -125 15N ppm, magnified in the blowout, 
has significant signal overlap and a high degree of ambiguity caused by repeating 

































































Therefore, Nd SET was divided into three separate constructs, each overlapping 
by 30-40 amino acids (Fig. 6, lower panel). There is the risk of losing secondary structure 
by truncating the protein. However, secondary structure is not necessary for backbone 
assignments of proteins. Regardless, due diligence was executed by comparing the crystal 
structure with multiple secondary structure predications, the truncation sites were 
designed to fall within regions of random coil, so as to preserve secondary structure (Fig. 
7, upper panel). A ‘divide-and-conquer’ methodology will help deconvolute regions of 
spectral overlap by allowing smaller fractions of these residues to be extracted for 
assignment. Figure 8 shows the two dimensional experiments for each of the truncated 
SET proteins except for TRUNC SET 1, which aggregates during the purification process 
and could not be used for an NMR spectroscopic experiments. These two-dimensional 
experiments establish a fingerprint for the protein where each peak corresponds to an 
amino acid of the protein being examined. The black arrows show common peaks 
between constructs, indicating residues in the regions designed to overlap (Fig. 10). As 
shown in Figure 10a-b, truncated SET constructs demonstrated significantly improved 
peak resolution. This shows that the ‘divide-and-conquer’ methodology will help with 
additional assignments. Identical triple resonance experiments were then performed on 
[1H-13C-15N]-labeled TRUNC SET 2 (55% assigned) and TRUNC SET 3 (57% assigned). 
Each spectra was then be overlaid and assignments transferred onto larger and larger 
spectra. The final assignments were transferred to a NdCd SET [1H-15N] TROSY (Fig. 




















Figure 10| [1H-15N] HSQC of TRUNC SET 2 and 3. 
(a) [1H-15N] HSQC spectra of TRUNC SET 2 (b) [1H-15N] HSQC spectra of TRUNC 
SET 3. (c) Overlaid [1H-15N] HSQC spectra of TRUNC SET 2 and TRUNC SET 3. 
Arrows indicate identical peaks used as reference points. (d) Overlaid [1H-15N] HSQC 
spectra of TRUNC SET 2 and NdCd SET. Arrows indicate identical peaks used as 
reference points. 
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Figure 11| Assigned [1H-15N] TROSY spectra of NdCd SET. 
Backbone assignments compiled from NdCd SET and TRUNC SET 2. Residues and 
assignments from TRUNC SET 3 are not present in the engineered NdCd SET construct. 






 The backbone assignment of NdCd SET proved to be very difficult. Firstly, NdCd 
SET, although only 24 kDa, behaves like a much larger protein due to its propensity to 
form dimers (48 kDa) and tetramers (72k kDa) (this will be discussed in more detail in 
the next chapter). This resulted in a high degree of peak overlap and poor signal to noise 
cause by unfavorable relaxation properties. The resultant signal degeneracy made 
connecting related spin systems in long stretches extremely difficult. We alleviated the 
unfavorable relaxation properties to some extent by deuterating the sample and 
employing a divide-and-conquer approach. However, it was not enough to complete a full 
backbone assignment and collect the additional data necessary to solve an NMR solution 
structure. Ultimately resulting in 54% total assignment of NdCd SET. Dedicated, full-
time NMR analysis could potentially increase the backbone assignment percentage, but it 
would take extensive protein engineering and time due to trial and error. Perdeuteration 
of the TRUNC SET constructs may help generate additional assignments by reducing 
unfavorable relaxation properties. Alternatively, If a construct of SET that preferred a 
monomeric state could be designed, while maintaining native secondary structure it may 
be possible to complete backbone assignments and solve an NMR solution structure. This 
would entail making a series of mutations within the dimerization domain of SET (E25- 











































Extended conformation of D-erythro-C6-pyridinium ceramide is favored, 
stabilized upon binding to Nd SET  
 
To uncover the molecular details of ceramide binding to SET, we first set out to 
determine lipid-binding from the perspective of ceramide. Previous data suggested that 
ceramide binds to SET in an “extended” conformation97, in which the sphingosine 
backbone and fatty acyl chains are extended away from each other to form a long, almost 
linear chain. In the “compact” conformation, sphingosine backbone and fatty acyl chain 
run parallel to each other on the same side of the molecule (Fig. 12).  We decided to use 
D-erythro-C6-pyridinium ceramide (C6P) to test whether SET binding requires an 
“extended” versus “compact” conformation. C6P is an established substrate for 
SET148,192, and the structure of the pyridine ring can act as a molecular probe during 
nuclear magnetic resonance (NMR) studies due to its unique chemical shift signature. To 
begin, we utilized a construct with an N-terminal deletion (Nd) of 22 amino acids241 (Fig. 
13a). We purified both Nd-SETWT and Nd-SETK209D, a mutation that largely decreases 
ceramide-binding97, and confirmed their intact secondary structures using circular 
dichroism (Fig. 13a-c). The loss of 22 N-terminal residues did not affect ceramide 
binding, whereas K209D conversion causes a threefold reduction of ceramide-SET 
binding, as shown by isothermal titration calorimetry (Fig. 14a-c).  
The peaks of the raw data were integrated to create a Wiseman plot. An 
independent model was chosen to fit the isotherms. The stoichiometry is calculated as the 
x-axis value at the inflection point of an ITC sigmoidal curve. We assumed a 1:1 
stoichiometry. Interestingly, the stoichiometry for both SET constructs is approximately 
1:2 (n= ~0.5). Generally, knowledge of the reactant concentrations are the major source 
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of error in determining stoichiometry. This could be caused by the protein concentration 
being lower than we thought as a result of error in the measurement technique. The ligand 
concentration in the syringe could also be higher than originally calculated. More likely, 
it may allude to data showing SET as largely dimeric, which is consistent with the early 












Figure 12| Comparison of 'compact' vs. 'extended' ceramide conformations. 
In the “extended” conformation97, the sphingosine backbone and fatty acyl chains are 
extended away from each other to form a long almost linear chain. In the “compact” 
conformation, sphingosine backbone and fatty acyl chain run parallel to each other on the 
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Figure 13| Expression of recombinant Nd SET constructs. 
(a) Schematic representation of SET truncation. (b) CD spectra and Coomassie stained 
Nd-SETWT. Lane 1: Marker. Lane 2: 50mM Imidazole wash. Lane 3: Purified Nd-SET 
after gel filtration. (c) CD spectra and Coomassie stained Nd-SETK209D. Lane 1: 
Marker. Lane 2: Purified Nd-SETK209D after gel filtration. All CD scans were in 

















Figure 14| Isothermal titration calorimetry of D-erythro-C6-pyridinium ceramide 
and Nd SET. 
(a) Corrected heat rate per injection as a function of time for Nd-SETWT. (b) Corrected 
heat rate per injection as a function of time for Nd-SETK209D. (c) Compiled ITC data 
presented as mean of n =3 individual experiments ± SEM. For all experiments 0.05mM 
C6P was titrated into 300µL of 0.021mM Nd-SETWT or Nd-SETK209D, respectively, at a 
20˚C temperature lock. 
 
 






Then, the two-dimensional (NOESY) NMR data were collected on C6P in order 
to identify which protons make contact with or are in close proximity to the binding 
pocket of Nd-SETWT, and therefore obtain transferred magnetization. The 2D Nuclear 
Overhauser Enhancement Spectroscopy (NOESY) (Fig. 15a) provides information 
relating to distance between 1H spin systems in space. The insert of Figure 15a shows an 
expanded region of interest, the pyridine ring, and how the proton resonances are coupled 
within 3-4 bonds. Focusing on the aromatic region, the diagonal peak H26 at 8.15 ppm 
(black arrow) has two cross peaks at 8.62 (H36-H25) and 9.0 (H26-H27) ppm indicating 
that it is in close proximity to both of these protons, whereas the two remaining diagonal 
peaks, at 8.62 (H25) and 9.0 (H27) ppm, only associate with the proton at 8.15 ppm, and 
not with each other (Fig. 15b). These data tell us that the peak at 8.15 ppm is located 
between the protons corresponding to peaks 8.62 and 9.0 ppm on the pyridinium ring. 
The full spectrum (Fig. 15a showed that the diagonal peak H27 (green arrow) has weak 
aliphatic cross peaks at 2.06 ppm and 1.43 ppm indicating that this proton is closest to 
lipid backbone. There is also a weak cross peak H27-H1O1(at 4.65 ppm), suggesting this 
proton associates with a hydroxyl group of the polar head group. These weak cross peaks 
indicate transient NOEs, suggesting that the acyl chain is rotating around the amide bond, 
exhibiting a rotation between “extended” and “compact” conformation of C6P (Fig. 15b). 
The missing proton resonances are due to signal overlap, exchange, and shielding effects 





Figure 15| Nuclear Overhauser Enhancement spectroscopy of C6-D-e-
pyridinium-ceramide bromide. 
(a) [1H-1H] NOESY spectra of 0.5mM C6-pyridinium-ceramide. Data collected on 
C6-pyridinium-ceramide with 16 scans, 2048 points in the direct dimension, 256 
points in the indirect dimension, and 500 ms NOE mix time. Black arrows indicate 
NOE signals between the pyridinium ring and other regions of the ceramide.  (b) 
Green, red, and black arrows correspond to proton assignments on the aromatic ring. 
The orange double arrows indicates protons with weak NOEs between the sphingosine 
backbone and the pyridinium ring. 
 
 57 
Saturation Transfer Difference NMR was performed to map and assign protons on 
the C6-pyridinium-ceramide involved in SET binding243,244. STD-NMR takes the 
difference between ‘on-resonance and off-resonance’ experiments. On-resonance 
experiments selectively saturate proton magnetization of the protein by a series of 
Gaussian pulses targeting methyl groups 233. The saturation disseminates to other protons 
through intramolecular 1H- 1H cross relaxation pathways 245. This saturation is then 
transferred to bound ligand, where it persists even after ligand dissociation with the 
protein. Off-resonance experiments are used to generate a reference spectrum. The 
difference between the two yields only resonances that have undergone saturation 
transfer. Due to the lower concentration of protein and much faster T1 relaxation time its 
resonances are not usually visible.  
As a positive control we tested the STD-NMR on a known binding system of 
BSA and tryptophan, using sucrose as an internal negative control 246. The overlaid 
spectra show that tryptophan resonances (7-8 ppm) are present with increasing intensity 
as saturation times increase, while there are no sucrose resonances (3-4 ppm) present 
(Fig. 16a). As a negative binding control we ran STD experiments described below on 
0.5 mM C6P in the presence of BSA. In the aromatic region between 7.5- 9 ppm we see 
no resonance buildup, and this is the region in which we see the greatest buildup during 







Figure 16| Positive and negative controls for Saturation Transfer Difference 
experiments. 
(a) Tryptophan binding to BSA with a sucrose non-binding control to show pulse 
sequence works. The blue reference spectrum shows the hydrogen atoms of tryptophan 
and sucrose.  The red spectrum shows an STD experiment where Trp is binding to BSA 
but not sucrose. (b) Negative binding control of C6-pyridinium-ceramide. The blue 
spectrum is 0.5 mM C6-pyridinium-ceramide, 6.0 s saturation, in the presence of BSA. 





The Saturation Transfer Difference (STD) experiments on Nd-SETWT showed 3 
distinct resonances in the aromatic region of the STD-difference spectra that 
corresponded to the three resonances of the pyridine ring identified in Figure 15a-b. 
There are also three distinct resonances in the aliphatic region of the STD-difference 
spectra. The resonances were seen to grow with intensity over the course of the saturation 
buildup until they reach a plateau (~4.0 seconds), where the “free pool” of ligand is 
saturated with magnetization (Fig. 17a). An STD amplification factor (STD-AF) was 
determined in the form of STD-diff= (Io-Isat)/Io, where the difference (STD-diff) was 
normalized by dividing each signal intensity by the strongest signal in the reference 
spectrum 234 (Fig. 17b). The difference spectrum was calculated using STD-diff= Io-Isat, 
where Io is the reference spectrum, and Isat is the saturation spectrum. The difference 
spectrum shows only ligand resonances that are bound to the receptor protein, or any 
protein signals which are further removed using a spin-lock filter.  
The STD-AF was used to assess the absolute magnitude of the saturation transfer 
difference effect of a given proton. We detected maximal saturation around 4 s for each 
of the 3 aromatic peaks with H25 (7.98 ppm) peak acquiring the most magnetization 
followed by H27 (8.75 ppm) and H26 (8.43 ppm peaks). Proton signals detected within 
the aliphatic region of C6P, specifically 1.90 and 1.55 ppm, suggest the lipid backbone 
may also play a role in binding. However, degeneracy of aliphatic proton signals in two-
dimensional spectra made specific assignments impossible. It is important to note that the 
chemical shifts reported here are different from those noted for the structural assignment 
of C6-pyridinium-ceramide. This difference is due to the fact that the structural 
assignment experiments were performed in methanol while all STD experiments were 
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carried out in PBS. Interestingly, data revealed that the conformation of C6P changes 
upon binding to SET. The proton at 8.75 ppm on the pyridine ring had strong interaction 
with SET (76% magnetization compared to the proton H25). These data suggested that 
C6-pyridinium-ceramide adopts an ‘extended’ lipid conformation, which exposes this 
proton to the lipid-binding pocket of SET (Fig. 17c). Otherwise, the proton H27 (8.75 
ppm) on the pyridine ring would not gain magnetization in a “compact” conformation 
due to shielding by the sphingosine backbone. Thus, these data suggest that C6P binds 










Figure 17| Analysis of D-erythro-C6-pyridinium ceramide binding to SET by STD-
NMR. 
(a) STD-NMR saturation build-up of 0.5mM C6P from 0.25s to 5.0s. (b) STD-NMR 
build-up curves were calculated using STD-Amplification Factor Isotherm. (c) Proposed 

















D-erythro-C18 ceramide, but not its enantiomer L-erythro-C18 ceramide, 
binds SET 
 
To continue the analysis of ceramide-SET binding we performed an in silico 
prediction using Molecular Operating Environment (MOE) to look at ‘hot spots’ or sites 
with a potential or propensity to bind lipid. This analysis tool calculates the relative 
positions and accessibility of the receptor atoms using the amino acid composition, such 
as hydrogen and hydrophobic interaction potentials247. The ligand binding prediction 
model shows three possible regions for lipid binding, 1: at the interface between the N-
terminal helix and globular domain, 3: the cleft created by two anti-parallel beta sheet 
stabilized loops and an alpha helix, and 2: at the base of the globular domain (Fig. 18). 
However, the interface between the N-terminal helix and globular domain predicts as the 
most likely area on SET to engage a ligand (Fig. 18). That region is marked as an area to 
monitor closely in subsequent binding experiments.  
To analyze the effect of lipid-binding on SET, we engineered a double truncation 
SET construct (NdCd-SET) where 52 C-terminal residues (consisting of a long 
unstructured acidic tail) were deleted in addition to the 22 N-terminal residues (Fig. 19a). 
The size of the protein would be more amenable to NMR spectroscopy, while still 
containing the putative lipid-binding pocket9. NdCd-SET was purified to >95% purity, 
and we confirmed its native secondary structure using circular dichroism (Fig. 19b-c). 
We then performed titrations of D-e-C18-ceramide and L-e-C18-ceramide (Fig. 20) 
against 15N-labeled NdCd-SET and monitored chemical shift perturbations (CSP) via 
[1H-15N] Transverse Relaxation Optimized Spectroscopy (TROSY). Ceramides were 
added to 0.9 mM 15N-labeled NdCd-SET in 0.5 µM increments at 0.5-10 µM. The CSP 
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calculations showed that D-e-C18-ceramide, but not L-e-C18-ceramide, binds SET (Fig. 
21a-c). The perturbations exhibited organized and confined clusters with increasing 























Figure 18| In silico prediction of ligand binding 'hot spots' on SET.  
The propensity of ligand binding prediction model run in MOE shows three, labeled as 
1,2, and 3, possible regions for lipid binding (in grey). The area between the N-terminal 






















Figure 19| NMR compatible NdCd SET construction for expression. 
(a) Graphic representation on recombinant SET proteins used in this study. (b) CD 
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Figure 20| D-erythro vs. L-erythro stereochemistry. 
The stereochemistry of ceramides is derived from the substitutions on carbons 2 and 3 of 
the sphingosine backbone. D-erythro is the naturally dominant conformation, making its 































































[15N] NdCd SET 
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Figure 21| Chemical shift perturbations of D-erythro and L-erythro-C18 ceramides. 
(a) [1H-15N] TROSY spectra of 0.9 mM NdCd SET. Expansion of spectral regions showing 
specific residues perturbed upon binding with D-e-C18-ceramide. (b) CSP of NdCd SET 
induced by 3 µM (black bars), 7 µM (red bars), and 10 µM D-e-C18-ceramide (blue bars) 
as a function of assigned residue. (c) CSP of NdCd SET induced by 3 µM (black bars), 7 
µM (red bars), and 10 µM L-e-C18 ceramide (blue bars) as a function of assigned residue. 
All CSP titrations were performed in triplicate. Red line is calculated as 3σ, and any value 





















The modeling and simulations were performed using Molecular Operating 
Environment (MOE 2018, Chemical Computing Group, Inc). Prior to simulations the 
monomer was isolated for the SET structure (pdb2E50: PMID 17360516) and protonated 
at T=310K, pH 7.3, salt at 200mM using GB/VI electrostatics248. We defined the ligand 
binding site using the chemical shift data as area constraints. We performed two iterative 
induced fit docking simulations.  The first simulation allowed access to the entire protein; 
the second round used the top pose from the first round and used the ligand atoms as the 
site to be probed. The docking simulations used induced fit for the receptor and flexed the 
ligand. For each docking simulation the initial placement calculated 50 poses using 
triangle matching with London ∆G scoring, then the top 20 poses were refined using 
forcefield (Amber10:ETH) and Affinity ∆G scoring (Escore2).  The affinity ∆G score is a 
linear function that estimates the enthalpic contribution to the free energy of binding. It 
was chosen due to an explicit hydrophobicity term, whereas most common scoring 
schemes use Van der Waals as a surrogate. The top 10 poses from these simulations were 
analyzed, and the final best pose was chosen based on being in concordance with the both 
CSP and ligand-observed NMR data followed by best E_score2 (Fig 22). 
The final ceramide-SET model determined using the CSP data as constraints 
showed ceramide in an ‘extended’ conformation oriented along the interface between the 
helix of the dimerization domain and beta sheets in the globular region (Fig. 23). The 
polar head group of ceramide is stabilized by E111 and V112 (Fig. 24). The sphingosine 
backbone may be stabilized by hydrophobic interactions with Y127 (Figs. 23 and 24). 
The acyl chain appeared to be free to intercalate a cleft created by two anti-parallel beta 
sheet stabilized loops and an alpha helix (Figs. 23 and 25). Chemical shifts occurring 
 70 
away, some highlighted in blue (Fig. 23), from the binding pocket were suspected to be 
the result of slight structural changes as the protein structure tightens around the lipid. 
Thus, these data suggest that ceramide binding results in site specific conformational 
























Figure 22| Ranking of the top 20 Affinity scores for SET D-erythro-C18 ceramide 
modeling 
Affinity ∆G (E_score2) rank for the top 20 poses. The lower the score, the more 
favorable the pose. Mathematical representation of Affinity ∆G (E_score2), where the 
hydrophobicity term is underlined. ‘hh’ represents hydrophobic interactions, for example, 








Figure 23| Pose of D-erythro-C18 ceramide-bound SET. 
Model of D-e-C18-ceramide-bound SET. Residues colored blue and green underwent a 














Figure 24| Interaction diagram of SET and D-e-C18 ceramide binding 
Interaction diagram of D-e-C18-ceramide binding suggests that one of the prominent 




Figure 25| Molecular Surface-filled model of D-e-C18 ceramide and SET binding 
The fill model applies a ‘skin’ to both the lipid and protein by covering the Van der 
Waals surface of the molecule while filling in solvent inaccessible gaps. The grey 






N-terminal helix is necessary for SET-FTY720 or SET-ceramide binding  
 
In order to define the precise nature of the SET-FTY720 complex, we again 
employed a ligand-observed NMR strategy. 1D and 2D NMR spectra were collected on 
FTY720 in the presence and absence of SET protein. It was found that FTY720 was 
incompatible with STD-NMR experiments due to false positive signals generated during 
control experiments. As an alternative, we employed 2D [1H-1H]-TOtal Correlational 
SpectroscopY (TOCSY) in which we monitored FTY720 as a function of Nd-SET 
concentration. One drawback to this approach is that signals arising from protein 
aliphatic protons obscure aliphatic FY720 peaks, therefore preventing their use in binding 
quantification. To overcome this limitation, we instead focused on FTY720 peaks found 
in the less-crowded aromatic/amide region (7.0-8.0 ppm), specifically N1-H1, C5,C3-H1, 
and C2,C6/C3C5-H1 cross peaks. As expected, we observed peak broadening 








Figure 26| Aromatic and amine groups of FTY720 are important for binding to 
SET. 
[1H-1H] TOCSY spectra of FTY720. Quantitation of line broadening as a function of 
peak volume and increasing concentration of Nd SETWT (0-50 µM). Chemical structure 
of functional groups on FTY720 affected by the addition of Nd SET. 
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Next, we titrated FTY720 against 15N-labeled NdCd-SET, and monitored CSP by 
[1H-15N] TROSY spectra (Fig. 27a-b). The modeling and simulations were performed 
using MOE 2018 (Chemical Computing Group, Inc). The same methodology was used 
with as outlined on page 62. The top 10 poses from these simulations were analyzed, and 
the final best pose was chosen based on being in concordance with the both CSP and 
ligand-based NMR data followed by best E_score2 (Fig 28). 
Similar to D-e-C18-ceramide, the perturbations resulted in confined binding 
clusters with increasing amounts of FTY720 (0.5-10 µM) (Fig. 29). The final pose for 
FTY720 in complex with NdCd-SET was strikingly similar to the C18-ceramide/NdCd-
SET model, highlighting an overlapping set of  protein residues that define the lipid-
binding  pocket. These include R64, Q65, F68 and R69  of  the helical dimerization 
domain, and residues E111, V112, and W213 found in the globular region (Figs. 29 and 
30). Interestingly, with both FTY720 and C18-ceramide poses, a similar conformational 
transition from alpha-helix to random coil in the N-terminal helix was predicted by 
molecular modeling and simulations (Figs. 25 and 29). Based on these data, E111 appears 
to play an important role in stabilizing the head groups of ceramide and FTY720 (Figure 
30). Data also indicate that R71 may be a key mediator of the FTY720-SET interaction, 
while D-e-C18 ceramide did not show any association with R71 (Fig. 26 and 30). This 
interaction between FTY720 and R71 of SET seemed to be driven by an electrostatic 
cation/π-arene mechanism (Fig. 30). The structural data also suggested that FTY720 is 
more buried in the cleft created by two anti-parallel beta sheet stabilized loops and an 
alpha helix than ceramide (Fig. 31). To account for protein specificity, FTY720 was 
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titrated against Immunoglobulin 1. The CSP was calculated, and showed no significant 





Figure 27| Chemical shift perturbations caused by the addition of FTY720. 
(a) [1H-15N] TROSY of NdCd SET. Expansion of spectral regions shows specific shifts 
upon FTY720 binding. (b) CSP of NdCd SET induced by 3µM (black bars), 7µM (red 
bars), and 10µM FTY720 (blue bars) as a function of assigned residue of n= 3 trials. Red 












[15N] NdCd SET 
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Figure 28| Ranking of the top 20 Affinity score for FTY720/SET binding 
Affinity ∆G (E_score2) rank for the top 20 poses. The lower the score, the more 
favorable the pose. Mathematical representation of Affinity ∆G (E_score2), where the 
hydrophobicity term is underlined. ‘hh’ represents hydrophobic interactions, for example, 





Figure 29| Model of FTY720-bounnd SET. 












Figure 30| Interaction diagram of SET and FTY720 binding 
Interaction diagram FTY720-SET binding generated using MOE suggests that one of the 
prominent binding sites includes the E111 and R71 residues, which electrostatically 




Figure 31| Molecular Surface-filled model of FTY720 ceramide and SET binding 
The fill model applies a ‘skin’ to both the lipid and protein by covering the Van der 
Waals surface of the molecule while filling in solvent inaccessible gaps. The grey surface 
represents Van der Waals, and the orange surface shows lipid hydrophobicity. FTY720 
fully intercalates into the core of SET. 
90˚ 
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The N-terminal helix containing the dimerization domain of SET seems to be 
important in both FTY720 and D-e-C18 ceramide binding. To test this, we used the 
TRUNC-SET-2 recombinant protein (Fig. 30a-c), which lacks the entire N-terminal helix 
in a titration against FY720 while monitoring CSP by [1H-15N] TROSY spectra. There 
were no chemical shifts detected on TRUNC-SET-2 with FTY720 (Fig. 30d). Thus, these 

































Figure 32| N-terminal helix containing the dimerization domain is essential for lipid-
binding. 
(a) schematic representation of recombinant SET used in this study. (b) model of SET 
truncation, illustrating the loss of the N-terminal helix. (c) Coomassie stained gel and CD 
spectra showing folded protein with a high percentage of random coil and β-sheets. (d) 
[1H-15N] TROSY spectra overlay of TRUNC SET 2 with and without 10µM FTY720, 
demonstrating no chemical shifts. (e) CSP of Immunoglobulin 1 (GB1) and 10µM 
FTY720. Lack of significant CSP indicates protein specificity. CSP titrations were 
performed in triplicate. Red line is calculated as 3σ, and any value greater than 3σ is 




















To validate residues of SET that may be important for ligand binding, identified 
by both NMR and pose data, we generated two SET mutants, SETE111A and SETR71A that 
should attenuate FTY720 binding. Circular dichroism showed the mutants retain intact 
secondary structure when compared to SETWT (Fig. 33 and 34d-g). Proximity ligation 
assays (PLA) were performed to measure the association of PP2A-C and FLAG-SETWT, 
FLAG-SETR71A, or FLAG-SETE111A (Fig. 34a-b) in A549 cells using anti-PP2AC and 
anti-FLAG antibodies with and without FTY720 (5 µM for 3 h). This treatment regime 
did not affect cell growth (Fig. 34c). Data showed that FTY720 reduced the association 
between PP2A-C and FLAG-SETWT. However, mutants of SET with R71A and E111A 
conversions showed no reduction in FLAG-SET-PP2AC association in response to 
FTY720, supporting that R71 and E111 play key roles in FTY720 binding, as suggested 




















































Figure 33| R71A and E111A mutations do not cause protein unfolding 
Circular dichroism shows similar secondary structure between SETWT, SETR71A, and 
SETE111A indicating no major changes in overall protein structure as a result of mutations. 
Helix: 26% 
β-strand: 24% 
random coil: 38% 
Helix: 3% 
β-strand: 42% 
random coil: 56% 
Helix: 10% 
β-strand: 41% 
random coil: 44% 
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Figure 34| Arg71 and Glu111 play key roles in FTY720 binding. 
(a) association between endogenous SET, Flag-SETWT, Flag-SETE111A, and Flag-SETR71A 
mutants and PP2AC ± 5 µM FTY720 was monitored by PLA using antibodies against 
SET, Flag, or PP2AC. SET mutants were generated from CSP and modeling. 
Representative images of n ≥ 3 independent experiments per group. Scale bars represent 
100 µm. (b) quantitation of PLA for SET mutants designed to limit response to FTY720 
treatment. Data are means ± S.E.M. of n ≥ 3 independent experiments per group, 




























analyzed by two-way ANOVA with Tukey’s post hoc test (*p = 0.0391, **p = 0.0259, 
***p = 0.0083). (c) Trypan blue counts of FTY720, D-e-C18, L-e-C18, and D-e-C6-pyr-
ceramides at twice the concentrations used in experiments to show changes in SET 
oligomerization are not a result of cell death. Error bars represent the SD of mean from 
triplicate experiments. (d) expression of R71A and E111A Flag-SET constructs. (e) 
quantitation of E111A and R71A Flag-SET normalized to actin. (f) SET expression 
knocked down with shRNA to the 3’UTR. (g) quantitation of SET knock down 


































FTY720-binding unravels SET dimerization domain 
 
Early characterization showed SET to exist primarily as a dimer and tetramer both 
in vitro and in HeLa cells via a combination of chemical cross-linking and analytical gel 
filtration182,235,242,249. Recombinant Nd SET was also observed as both dimer and 
tetramer241. A region between residues 36-124 near the N-terminus is critical for PP2A 
inhibition180. Additionally, this region contains a coil-coiled domain (E25-Q65), which 
controls SET dimerization182. Together these data suggest SET dimerization or even 
oligomerization may be necessary for PP2A inhibition.  
NMR titration data, and the associated lipid-binding simulation models generated 
with MOE, suggest that FTY720 or ceramide binding may modulate secondary structure 
within the N-terminal alpha helix between Gln29-Lys77. Interestingly, TROSY peaks 
corresponding to these residues appeared to undergo line broadening upon the addition of 
FTY720 during NMR titrations (Fig. 35a-c). This region encompasses SET’s 
dimerization domain and may coincide with the disruption of the dimerization interface, 
which subsequently could prevent SET from forming dimers and/or higher order 
oligomers.  In order to rule out protein degradation as a major contributor to this 
phenomenon, [1H-1H] 1D spectra were collected before each [1H-15N] TROSY. 
Hallmarks of degraded protein shows peaks sharpening and collapsing back to the 
baseline, especially in the amide region, and the methyl peaks, located between 0 ppm 
and -1 ppm disappear as a result of protein degradation. [1H-1H] 1D spectra indicate there 
were no major changes to indicate protein degradation, with or without 10 µM FTY720 
(Fig. 36). This could indicate that lipid binding results in structural changes in the N-
terminal alpha helix between Gln29-Lys77, which subsequently would prevent SET from 
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forming dimers/oligomers, which are active forms of SET182,242. More work will need to 










Figure 35| Lipid-Binding may alter SET dimerization domain to prevent 
oligomerization 
(a) Spectrum of highlights peaks that undergo line broadening upon the addition of FTY720. 
These peaks correspond to residues in the dimerization domain of SET. Blowout highlights 
broadened peaks (red) at 10 µM FTY720. (b) Quantitation of the change in peak height of 
assigned residues in the dimerization domain. Data are means n=3 experiments. (c) Comparison 
of NdCd SETWT models in the absence (white) and presence (blue) of D-e-C18 ceramide 














































Figure 36| Line broadening is not related to protein degradation during NMR 
titrations. 
Overlaid [1H-1H] 1D spectra of NdCd SET ± 10 µM FTY720 (red and blue, respectively) 
showing no protein degradation. Area between 4.5 ppm and 5.5 ppm excluded due to 














The motion of molecules in solution is dependent on physical parameters such as 
size and shape of the molecule, temperature, and viscosity. A diffusion profile is 
measured by signal attenuation as a function of linearly increasing field gradient. A 
molecule can be spatially labeled in the sample tube and its motion/diffusion tracked. A 





The rate of diffusion is inversely related to molecular weight (i.e. a small diffusion 
coefficient = a large molecule). Pulsed field NMR experiments can be collected in 30 
minutes or less with high resolution. We believed this would be a quick, straightforward 
approach to determine if lipid-binding prevents SET dimerization. 
Then, we performed Diffusion-Ordered Spectroscopy (DOSY)250–252 on NdCd-
SET, which contains Gln29-Lys77, with and without FTY720 (Fig. 37). We generated a 
standard curve of apparent molecular weight using typical low molecular weight marker 
proteins (Fig. 37a)253 to calculate an apparent molecular weight of SET with and without 
FTY720. If lipid-binding prevents dimerization, it is expected to cause an increase in the 
diffusion coefficient, representing a decrease in apparent molecular weight. Simply 
stated, the rate of diffusion is inversely related to the weight/size of the molecule. The 
data showed that NdCd-SET alone exhibited a diffusion coefficient of 0.591/10-10m2s-1 
giving an apparent molecular weight of 49.1 kDa, representing a dimer (Fig. 37b, upper 
panel). However, NdCd-SET with 10 µM FTY720 binding had a diffusion coefficient of 
1.057/10-10m2s-1, giving an apparent molecular weight of 22.3 kDa, representing a 
monomeric state (Fig. 37b, lower panel). Intriguingly, the sample with FTY720 exhibited 
a much broader diffusion peak. This could be due to the presence of species of SET as it 
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transitions from oligomers (in lower abundance) to monomers, causing a broadening of 


























Figure 37| Exposure to FTY720 lowers apparent molecular weight of NdCd SET. 
(a) DOSY spectra and diffusion coefficients ±10 µM FTY720 were analyzed with 
DOSYToolBox 2.7 253. (b) list of proteins used to make standard curve and their 
molecular weights. (c) standard curve of apparent molecular weights of proteins 
generated by diffusion ordered spectroscopy (DOSY). 
 
 





To determine if the prevention of SET dimer/oligomer formation could occur in 
cells, A549 cells were treated with FTY720, D-e-C18, and L-e-C18 ceramides for 3 h, 
and SET oligomerization was analyzed by Western blotting after chemical crosslinking 
of proteins using glutaraldehyde. Data showed that SET exists primarily as a dimer and 
tetramer (oligomers) with low monomeric protein abundance in A549 cells, as expected 
(Fig. 38a). When treated with FTY720 (Fig. 38c-d) and D-e-C18 ceramide there was a 
sharp reduction in SET oligomer formation. L-e-C18 ceramide had no effect on reduction 
of SET oligomers (Fig. 38c-d). These data were also confirmed using the mutants of SET 
with reduced FTY720 binding, which remained as oligomers with/without FTY720 (Fig. 
38e-f). Taken together, these data suggest that lipid-binding causes structural changes in 
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Figure 38| SET exists primarily as a dimer and tetramers (oligomers) with low 
monomeric protein abundance. 
(a) representative blot for glutaraldehyde (GA) crosslinking of endogenous SET 
oligomers ± 5 µM FTY720 and 0.01% GA. (b) quantitation of crosslinking experiment. 
Representative blot of n= 3 individual experiments. Blots were quantified with ImageJ.  
Data are means normalized to actin ± S.D. and analyzed by two-way ANOVA with 
Tukey’s post hoc test (*p < 0.0001, **p < 0.0001, ***p < 0.0001). (c) glutaraldehyde 
(GA) crosslinking of SET oligomers in response to 3 hrs. treatment with 1-5 µM D-e-C18 
or L-e-C18-ceramides. Representative blot of n= 3 individual experiments. (d) Model 
showing prevention of SET oligomerization due to binding with FTY720 (*p< 0.05, 
**p< 0.01, ***p<0.00 and ****p< 0.0001). Data were analyzed by student’s t-test. (e) 
representative blot for glutaraldehyde (GA) crosslinking of SETWT, SETR71A, and 
SETE111A oligomers ± 5 µM FTY720 and 0.01% GA. (f) quantitation of GA crosslinking. 
Representative blot of n= 3 individual experiments. Blots were quantified with ImageJ.  
Data are means normalized to actin ± S.D.  and analyzed by two-way ANOVA with 



















The work of this chapter proposes a possible mechanism to how ceramide or 
FTY720 interact with SET, leading to PP2A activation. Our data are consistent with 
previous findings that showed the N-terminal region (36-124) is essential for PP2A 
inhibition180. We show residues (R71 and E111) that may be essential for lipid-binding. 
Furthermore, we were able to show that ceramide is stabilized into the an ‘extended’ 
conformation upon binding to SET. In addition, the helical structure within the 
dimerization domain of SET is disrupted upon binding to FTY720 or ceramide, 
preventing oligomerization. Analysis of SET after crosslinking with GA shows a clear 
reduction in oligomerization. Therefore, we propose that SET oligomerization is essential 
for PP2A inhibition, since SET exists primarily as a dimer and tetramer within cells182,242. 
The fate of lipid-bound SET is unknown. It is important to note that the reduction in SET 
oligomers is not followed by a concomitant increase in monomeric SET (Fig. 38a). Still, 
the mechanism of PP2A activation through SET reaches beyond the realm of cancer 
biology into ceramide/SET/PP2A- mediated mechanisms of insulin resistance and 
vascular dysfunction in metabolic disease193,254–256.  In both instances, increased levels of 
ceramide activate PP2A, through SET, leading to antagonistic insulin signaling through 
the AKT pathway or eNOS related vascular contractility problems, respectively. Contrary 







































When examining the association of SETR71A and SETE111A with PP2A in the 
presence and absence of FTY720 we noted that endogenous SET and PP2AC have a very 
limited interaction (Fig. 34a-b).  SET is thought to inhibit PP2A directly by binding the 
C-subunit in vivo, but the specific interactions between SET and PP2A have not yet been 
described. PP2A is expressed in the cell ubiquitously, while SET is predominantly 
nuclear (Fig. 39a). Given the information available and common assumptions in the 
PP2A field, we thought that the cells would be saturated with PLA signal. However, 
closer examination by proximity ligation assay between endogenous SET and PP2AC in 
A549 cells show a very limited interaction (Fig. 39b).  This was very interesting because 
it intimated that SET possibly had a specificity for a unique heterotrimeric PP2A 
complex, and that this interaction may not be directly governed or limited to the catalytic 
subunit of PP2A. Both of these possibilities are dogmatic shifts in the PP2A field. To that 
end, we want to determine what unique heterotrimeric PP2A complex is activated by 
FTY720 or ceramide, possible downstream target(s), and if that complex is targeted by 















Figure 39| Endogenous SET and PP2A have minimal specific association within the 
cell. 
(a) Immune fluorescence microscopy demonstrating subcellular localization and relative 
expression of SET (cyan) and PP2AC (red). (b) association between endogenous SET 
and PP2AC monitored in A549 cells with and without 5 µM FTY720 treatment for 3 








FTY-720-SET interaction selectively activates a specific PP2A holoenzyme 
 
To determine downstream protein targets of PP2A in response to its activation by 
FTY720 upon SET binding and inactivation, we performed stable isotope labeling of 
cells in culture (SILAC) analysis by mass spectrometry. A549 cells stably overexpressing 
HA-tagged PP2ACα were grown in heavy (15N-arginine labeled) and light (normal) 
DMEM media. After three weeks of growing cells, the ‘heavy cells’ were treated with a 
high dose (20 µM) of FTY720 for 2 hours, washed, collected, and lysed. PP2ACα was 
immuno-precipitated by the HA-tag in both treated and control cells. The elution of 
control and treated samples were mixed and run on SDS-PAGE. The gel was then 
Coomassie stained for analysis by 
mass spectrometry. The ratio of 
15N:14N was analyzed for changes 
in protein levels as result of 
exposure to FTY720. 
The SILAC analysis 
resulted in over 130 possible 
proteins that increase or decrease 
association with PP2AC in response to FTY720 treatment. These proteins represented a 
wide array of cellular functions (Fig. 40). Interestingly, SET was not among the list, 
suggesting that FTY720 binding relieves SET from PP2AC, as we expected (Appendix 
II: Table 6). Several PP2A subunits were increased after FTY20 treatment, including 
PP2AAβ and PP2A-B56γ (Table 5). These data suggested that FTY720-mediated 
activation of PP2A might require a selective PP2A holoenzyme with specific A, B and C 
Table 4: SILAC Results of PP2A-related 
subunits 








subunits. To test this hypothesis, we generated stable shRNA-dependent knockdown of 
each PP2A subunit identified by SILAC analysis in A549 cells (*see Fig. 53 in Appendix 
II for blots of knockdowns and shRNA sequences). We then assessed whether the loss of 
the subunits perturbed by SET-FTY720 association affected SET-PP2A interaction by 
PLA (Fig. 41a-c). We further hypothesized that loss of SET-PP2A association (loss of 
PLA signal) in a particular knockdown cell line would indicate that an individual subunit 
was important for SET-PP2A interaction. The data showed that shRNA-mediated 
knockdown of PP2AA a or β, PP2A-B56γ, and PP2ACα subunits decreased SET 
association, compared to Scr-shRNA, or shRNAs against PP2AAα, PP2A-B56𝛿, or 
PP2ACβ (Fig. 41a-c). Furthermore, we assessed PP2A activation in shScr, shPP2ACα, 
shB56γ, and shB56𝛿 stable cell lines in response to FTY720 by blotting for PP2A-
phospho-Tyr307. Phospho-Tyr307 is a marker of PP2A activity, where a decrease in 
phosphorylation correlates with an increase in PP2A activity. Exposure to FTY720 
increases PP2A activity (decreased p-Tyr307) in both the shScr and shB56𝛿	cells,	but	not	
the	 shB56γ cells, suggesting PP2A containing the B56γ subunit are responsive to 
activation by FTY720 (Fig. 41d-e).  Thus, these data suggest that FTY720-SET binding 
results in the selective activation of PP2A holoenzyme containing PP2A-Aβ, PP2A-
B56γ, and PP2ACα subunit (Fig. 41a-c). These data are consistent with tumor suppressor 
functions of B56γ subunit of PP2A, whose various mutations or changes in expression 









Figure 40| SILAC results divided by cellular function. 
Treatment with FTY720 causes increased associated between PP2ACα and many 
proteins. The largest group of proteins had structural and motility functions. Proteins 




































Figure 41| SET targets a specific heterotrimeric PP2A 
(a) Association between endogenous SET and PP2AC in shPP2AA⍺ and shPP2AAβ 
knockdown cells was analyzed by PLA. Data are means ± S.E.M. of n = 3 independent 
experiments, analyzed by student’s t-test (*p = 0.0388). (b) Association between 
endogenous SET and PP2AC in shB56ɣ and shB56𝛿 knockdown cells was examined by 
PLA. Data are means ± S.E.M. of n = 3 independent experiments, analyzed by student’s 
t-test (*p = 0.0001, **p = 0.0147) (c) association between endogenous SET and PP2AC 
in shPP2AC⍺ and shPP2ACβ knockdown cells was assessed by PLA. Data are means ± 
S.E.M. of n = 3 independent experiments, analyzed by student’s t-test (*p = 0.0008, **p 
= 0.0114). (d) Western blot of PP2AC phosphor-Tyr307 as a marker for PP2A activity. (e) 
quantitation of p-Tyr307 blots. Representative blot of n= 3 individual experiments. Blots 
were quantified with ImageJ.  Data are means normalized to actin ± S.D. and analyzed by 
two-way ANOVA with Tukey’s post hoc test (*p < 0.0001, **p < 0.0001, ***p < 
0.0001). 
a c b 
+ - + + + - - - 
shSCR shPP2AC⍺ shB56ɣ 








Moreover,  exogenous expression of HA-PP2AC⍺, but not HA-PP2ACβ, in 
shPP2AC⍺-transfected cells restored SET-PP2AC⍺ interaction, which was then inhibited 
by FTY720 (Fig. 42a-b). Similarly, expression of exogenous B56γ-V5, and not B56𝛿-V5 
(Fig. 42c), in shB56γ-transfected cells restored SET-PP2AC⍺ association, which was also 
inhibited by FTY20 (Fig.  42d). Thus, these data reveal that SET preferentially associates 
with a PP2A holoenzyme composed of PP2AAβ, B56γ, and PP2ACα subunits in A549 
cells. 
Remarkably, SET remained in complex with PP2A-B56γ with or without FTY720 
or C18-ceramide (Fig. 43a-b). As a control, we used a peptide inhibitor of SET, OP449208 
with an unknown mechanism of SET inhibition for measuring its effects on SET-PP2A-
B56γ association. Data showed that OP449 had significant reduction in the interaction 
between SET and PP2A-B56γ while also decreasing SET-PP2ACα association (Fig. 43a-
c). The data suggests that SET is not a universal inhibitor of all PP2A holoenzymes, and 
that it targets, as a dimer/tetramer, a specific PP2A hetero-trimer through interacting with 











Figure 42| Reconstitution of PP2AC⍺ and B56g expression restores SET/PP2A 
association 
(a) Western blot showing successful reconstitution of expression for HA-PP2AC⍺ and HA-
PP2ACβ. (b) association between endogenous SET and HA-tagged PP2AC in shPP2AC⍺ and 
shPP2ACβ stable knockdown cells with rescued expression (shPP2AC⍺ + HA-PP2AC⍺ and 
shPP2ACβ + HA-PP2Acβ)  was assessed by PLA using antibodies against SET and HA epitope. 
Quantitation of PLA. Data are means ± S.E.M. of n = 3 independent experiments, analyzed by 
student’s t-test (****p<0.0001). (c) Western blot showing successful reconstitution of expression 
for V5-B56g and V5-B56d. (d) association between endogenous SET and PP2AC in shB56g and 
shB56d stable knockdown cells with rescued expression (V5-B56g and V5-B56d) was assessed 
by PLA using antibodies against SET and PP2AC. Quantitation of PLA. Data are means ± S.E.M. 







Figure 43| SET remains in complex with PP2A-B56γ after exposure to FTY720 or D-
erythro-C18 ceramide 
(a) association between endogenous SET/PP2AC and SET/B56ɣ ± 5 µM FTY720, 5 µM 
D-e-C18 ceramide, or 1 µM OP449 treatment for 3 h assessed by PLA using antibodies 
against SET, PP2AC, and B56ɣ. Representative images of n ≥ 3 independent experiments 
per group. Scale bars represent 100 µm. (b, c) quantitation of PLA experiments. Error 
bars are SEM of n ≥ 3 independent experiments per group Data are means ± S.E.M. of n 
≥ 3 independent experiments per group, analyzed by two-way ANOVA with Tukey’s 
post hoc test (*p< 0.05, **p< 0.01, ***p<0.00 and ****p< 0.0001). 
 




















To further validate these data, we performed GST pulldown assays using various 
recombinant PP2A subunits and WT-SET with/without FTY720 in vitro. These studies 
demonstrated that SET preferentially associates with PP2AAβ-GST, and not with 
PP2AAα-GST in vitro (Fig. 44a). This interaction between SET and PP2AAβ-GST is 
reduced in response to FTY720 (50 µM)  (Fig. 44b). The pull-down assays also showed 
that FTY720 at 25, 50 and 100 µM reduced the interaction of SET with the in vitro 
assembled PP2A holoenzyme containing PP2AAβ-GST, PP2AB'γ1, and PP2ACα (Fig. 
44c). However, FTY720 (12.5-50 µM) had no effect on the interaction between SET and 
PP2AB'γ1-GST (Fig. 44d). These data revealed that while FTY720 inhibits the 
interaction between SET and PP2AAβ-GST, SET remains bound to PP2AB'γ1 
with/without FTY720 in vitro, consistent with data obtained in A549 cells.  
Taken together, these data suggest that SET might not be a universal inhibitor of 
all PP2A holoenzymes, and that it targets, as a dimer/tetramer, a specific PP2A 
holoenzyme composed of PP2AAβ, B56γ, and PP2ACα subunits. These data also suggest 
that although FTY720 inhibits the interaction between SET- PP2AAβ-PP2ACα complex, 
SET stays associated with B56γ with or without FTY720 in A549 cells (or with 












Figure 44| In vitro pull-down assays corroborate SET interaction with a specific 
PP2A holoenzyme 
(a) Pull-down assay with either GST-tagged PP2A core enzyme (AbCa or AaCa) and SET. (b) 
Pull-down assay with either GST-tagged PP2A core enzyme (AbCa) and SET with increasing (0-
50 µM) FTY720. (c) Pull-down assay with either GST-tagged PP2A holoenzyme (AbCaBg1) and 
SET with increasing (0-100 µM) FTY720. (d) Pull-down assay with either GST-tagged Bg1and 











Figure 45| Model of SET/PP2A complex and mode of activation with ligand. 
SET oligomerization is essential for PP2A inhibition. Lipid-binding prevents SET 
oligomerization resulting in active PP2A. Additionally, SET remains with FTY720-













Myosin IIa is targeted by FTY720-activated PP2A 
 
Because our data revealed that PP2A-B56γ plays a key role in the activation of 
PP2A by FTY720 upon SET binding/inactivation, and it is important for substrate 
selectivity of the PP2A holoenzyme, we then assessed whether tumor suppressor non-
muscle myosin IIa (MYH9) , identified as one of the highly PP2A-associated proteins 
after FTY720 activation in SILAC (Appendix II, Table 7),  is targeted by activated PP2A 
holoenzyme containing PP2AA, PP2A-B56γ, and PP2ACα. To test this, we performed 
PLA between PP2AC and myosin IIa in sh-SCR and sh-PP2A-B56γ stable knockdown 
cell lines with and without treatment of 5 µM FTY720 for 3 h. We detected an increase in 
association of PP2AC and Myosin IIa in shSCR cells after treatment with FTY720. 
However, when we knocked down PP2A-B56γ, the association between PP2AC and 
myosin IIa was completely abrogated with/without FTY720 (Fig. 46a-b). Additionally, 
when we used non-muscle myosin IIa isolated from rabbit as a substrate for partially 
purified PP2AC in vitro, the data showed increased PP2A activity after treatment with 
FTY720 in shSCR transfected cells against purified myosin IIa, but not in cells 
transfected with shB56γ (Fig. 47a-b). Overexpressing SETR71A or SETE111A, both of 
which showed decreased FTY720 response, also resulted in decreased PP2A activity  
(Fig. 48a-b). Thus, these data suggest that the activation of a specific PP2A holoenzyme 
in response to FTY720-SET binding, containing PP2AA, PP2A-B56γ, and PP2ACα 
subunits selectively targets various downstream proteins, such as tumor suppressor non-





Figure 46| Myosin IIa is targeted by FTY720-activated PP2A. 
(a) validation of PP2AC/Myosin IIa association observed in SILAC data. association 
between PP2AC and Myosin IIa in shSCR and shB56ɣ stable knockdown cell lines ± 
treatment of 5 µM FTY720 for 3 hrs by PLA using antibodies against PP2AC and myosin 
IIa. Representative images of n = 3 independent experiments. Scale bars represent 100 
µm. (b) quantitation of PLA experiments. Data are means ± S.E.M. of n = 3 independent 
experiments, analyzed by two-way ANOVA with Tukey’s post hoc test (*p = 0.0122, 














Figure 47| Myosin IIa is a potential substrate for FTY720-activated PP2A. 
(a) PP2A activity assay in shSCR and shB56ɣ stable knockdown cell lines ± treatment of 
5µM FTY720 for 16 h using purified rabbit non-muscle Myosin IIa as a substrate. Data 
are means ± S.D. of n = 3 independent experiments analyzed by two-way ANOVA with 
Tukey’s post hoc test (*p =  0.0096, **p = 0.0224). (b) Western blot of p-Tyr307 on 




+ + - - 
shSCR shB56ɣ 










Figure 48| SETR71A and SETE111A mutants reduce PP2A activation in response to 
FTY720. 
(a) PP2A activity assay in A549 cells transiently overexpressing WT, R71A, or E111A 
Flag SET ± treatment of 5 µM FTY720 for 16 h. using purified rabbit non-muscle 
Myosin IIa as a substrate. Data are means ± S.D. of n = 3 independent experiments 
analyzed by two-way ANOVA with Tukey’s post hoc test (*p =  0.0011, **p = 0.0007, 
***p = 0.0007).  (b) Western blot of p-Tyr307 on PP2AC, normalized to β-Actin and 
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experiments. Blots were quantified with ImageJ.  Data are means normalized to actin ± 
S.D. and analyzed by two-way ANOVA with Tukey’s post hoc test (*p < 0.0001, **p < 

































Phosphorylation of SET influences PP2A activity 
 
It is known that SET phosphorylation can increase or decrease its inhibitory 
function on PP2A in a site-dependent manner98,184–187. To examine whether SET-PP2A 
association controlled by FTY720 is also regulated by the phosphorylation status of SET 
in cells, we generated phospho-mimetic and non-phosphorylatable FLAG-tagged SET 
mutants of all known relevant sites, including S9E, S9A, S24E, S24A, S93E, S93A, 
Y133E, Y133F, Y133A, S171E, and S171A (Fig. 49a-b). Then, effects of these 
mutations on FLAG-SET-PP2A-B56γ association and FLAG-SET-PP2ACα association 
were measured using PLA in A549 cells with shRNA-mediated stable knockdown of 
endogenous SET. Data showed that phosphorylation of only the S171 residue of SET 
plays a role in PP2A association in response to FTY720 (Fig. 49c).   
The SETS171A mutant showed significantly increased association with PP2A, 
while SETS171E showed a reduction in association when compared to SETWT (Fig. 49c, 
50a-b). The SETS171A mutation showed resistance to FTY720-induced disruption of 
association with PP2ACα (Fig. 50a-b). Both SETS171A and SETS171E showed association 
with B56γ comparable with SETWT with and without FTY720 treatment. These data also 
showed that SETS171A association with B56γ was elevated compared to SETWT and 
SETS171E (Fig 51a-b) with/without FTY720, which is consistent with the effects of 
SETS171A on resistance to decreased oligomerization by FTY720 (Fig. 52), resulting in 
resistance to PP2A activation in response to FTY720 (Fig 53a-b). These data support that 
dephosphorylation of SET at Ser171 plays a role in resistance to FTY720-mediated PP2A 
activation in A549 cells, and that both phosphorylated and non-phosphorylatable SET 




Figure 49| Expression of phospho-mimetic and non-phosphorylatable SET mutants. 
(a) Western blot for Flag-tag on phospho-mimetic and non-phosphorylatable SET 
mutants. (b) Quantitation of mutant Flag-tagged SET expression normalized to actin. (c) 
Association between Flag-SET mutants and PP2AC ± 5 µM FTY720 was measured by 
PLA using antibodies against Flag and PP2AC. Data are means ± S.E.M. of at least 3 















































































Figure 50| Phosphorylation at Serine171 influences SET/PP2A association. 
(a) representative images of PLA between endogenous SET, S171, and K209D Flag-SET 
mutants and PP2AC ± 5 µM FTY720 (n=3 independent experiments per group). Scale 
bars represent 100 µm. (b) association between endogenous SET, Flag-SETWT, Flag-
SETS171A, Flag-SETS171E, and Flag-SETK209D mutants and PP2AC ± 5 µM FTY720 with a 
pCDH empty vector control measured by PLA using antibodies against SET, Flag, and 
PP2AC. Data are means ± S.E.M. of n = 3 independent experiments, analyzed by two-





























Figure 51| SET Ser171 mutants remain in contact with B56g in the presence or 
absence of FTY720. 
(a) representative images of PLA between S171A and S171E Flag-SET and B56ɣ ± 5 
µM FTY720 (n=3 independent experiments per group). Scale bars represent 100 µm. (b) 
association between Flag-SETS171A and Flag-SETS171E and PP2A-B56ɣ ± 5 µM FTY720 
assessed by PLA using antibodies against Flag and B56ɣ. Data are means ± S.E.M. of n = 
3 independent experiments analyzed by two-way ANOVA with Tukey’s post hoc test (*p 































Figure 52| SETS171A retains oligomeric state in the presence of FTY720. 
Quantitation of glutaraldehyde (GA) crosslinking of Flag-SETWT, Flag-SETS171A, and 
Flag-SETS171E oligomers in response to 3 h treatment with 5 µM FTY720. Data are 
means ± S.D. of n = 3 independent experiments analyzed by two-way ANOVA with 
Tukey’s post hoc test (*p = 0.0321). Data are represented as a fold change compared to 



















Figure 53| Expression of SETS171A reduces activation of PP2A. 
(a) Western blot of p-Tyr307 of PP2AC as a marker of activity normalized to β-Actin and 
Flag expression. (b) quantitation of p-Tyr307 blots. Representative blot of n= 3 individual 
experiments. Blots were quantified with ImageJ.  Data are means normalized to actin and 
Flag ± S.D. and analyzed by two-way ANOVA with Tukey’s post hoc test (*p < 0.0001, 
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The SET/PP2A Complex may assemble and originate in the Endoplasmic 
Reticulum 
 
A persistent question in the SET/PP2A field is the source of the ceramide that 
bind SET. The simplest answer would be the source of ceramide with the cell; the ER. To 
this end, we examined if this specific SET/PP2A complex, containing PP2AA, PP2A-
B56γ, and PP2ACα, is localized in the ER prior to activation with FTY720. We 
monitored the subcellular localization of PP2A via the B56g subunit in response to 
FTY720 by immune fluorescence microscopy. Interestingly, we noted colocalization 
between B56g and Protein Disulfide Isomerase A2 (PDI), a rough ER marker (Fig. 54a). 
Upon treatment with FTY720, B56g shifted to the smooth ER (11b-HSD1 colocalization) 
(Fig. 54b). Eventually there was also formation of B56g puncta colocalized with GM130, 
a Golgi marker (Fic. 54c). The data suggested that FTY720-activated PP2A originates in 
the ER; therefore, we isolated the ER to look for both SET and PP2A. As SET is 
predominantly a nuclear protein, PP2A was immune-precipitated after purification of ER 
by ultra-centrifugation (Fig. 55) to enrich for both proteins and increase chances of 
detection. There is a reduction in SET/PP2A association with exposure to FTY720 (Fig. 
55). Furthermore, there is a reduction in both B56g and SET after treatment with FTY720 
(Fig. 55, right panel).  
To further confirm the ER localization of SET and PP2A, we engineered a GFP-
tagged SET to be retained in the ER (Fig. 56a-b). Ectopic expression of both SETWT-GFP 
and SETER-GFP showed that retention of SET in the ER increased association with PP2A 
(Fig. 56c). Together, these data support our proposed mechanism of PP2A activation via 
FTY720 or ceramide preventing SET oligomerization. It also suggests that the SET/PP2A 
complex originates in the ER. It is, therefore, likely that modulation of ceramide, which is 
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generated in the ER, influences SET oligomerization, PP2A activation, and subsequent 







Figure 54| B56g-containing PP2A translocate from the rough ER to Golgi after 
exposure to FTY720. 
(a) observation of subcellular co-localization of B56g with PDI ± 5 µM FTY720 for 3hr 
by immune fluorescence microscopy. (b) observation of subcellular co-localization of 
B56g with 11b-HSD1 ± 5 µM FTY720 for 3hr by immune fluorescence microscopy. (c) 
observation of subcellular co-localization of B56g with GM130  ± 5 µM FTY720 for 3hr 
by immune fluorescence microscopy. 
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Figure 55| The SET/PP2A complex is detected in the endoplasmic reticulum. 
(a) co-immune precipitation of PP2AC and SET from purified ER after exposure to 5 µM 
FTY720 for 3hr. PDI is an ER marker and TOM20 is a mitochondrial marker. ER was 
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Figure 56| Manipulation of SET subcellular localization enhances interaction with 
PP2A. 
(a) diagram comparing features of SETWT and SETER-GFP constructs. Both nuclear 
localization signals were removed and a KDEL ER-recycling sequence was added to the 
C-terminus. (b) Immune fluorescence microscopy comparing subcellular localization of 
ectopically expressed  SETWT and SETER-GFP. SETWT-GFP localized heavily to the 
nucleus while SETER-GFP remains more cytoplasmic. (c) Co-immune precipitation of 
SETWT and SETER-GFP with magnetic GFP-conjugated beads (Abcam). Detection of 









































 Data presented in this chapter show that the loss of specific PP2A subunits will 
disrupt SET-PP2A association, suggesting that SET inhibits a particular PP2A consisting 
of PP2AAβ, B56γ, and PP2ACα subunits. This suggests that the interaction may be more 
specific and that SET may not be a universal inhibitor of PP2A, as is widely believed. 
Moreover, at least a monomer of SET remains with FTY720-activated PP2A by 
maintaining contact with the B56γ subunit. The phosphorylation status of SET at S171 
also plays a key role in determining SET-PP2A association. This is most likely due to 
manipulation of subcellular localization. Serine 171 falls within one of SET’s nuclear 
localization signals. Literature suggests that dephosphorylation at this site increases the 
cytosolic abundance of SET by slowing its nuclear localization186. In this study, we also 
show data that suggest the SET/PP2A complex is loaded in ER and can egress to the 





















































SET overexpression is involved in many cancers, where it functions as an 
inhibitor of PP2A. Reactivation of PP2A by targeting SET is known to be a potent 
avenue of tumor suppression; however, the specific interactions between SET and PP2A, 
as well as the interaction between SET and FTY720 or ceramide, have been largely 
unknown.    
Here are described the first molecular details of sphingolipid-protein interaction 
by NMR spectroscopy. The structural work of this study proposes a possible mechanism 
as to how ceramide or FTY720 interacts with SET, leading to PP2A activation. The data 
reaches beyond the realm of cancer biology into ceramide/SET/PP2A-mediated 
mechanisms of insulin resistance and vascular dysfunction in metabolic disease193,254–256. 
In both instances, increased levels of ceramide activate PP2A, through SET, leading to 
antagonistic insulin signaling through the AKT pathway and eNOS-related vascular 
contractility problems. Contrary to cancer biology, the therapeutic goal would be to 
inhibit PP2A activity in metabolic disease. Overall, our data are consistent with previous 
findings that showed the N-terminal region (36-124) of SET to be essential for PP2A 
inhibition180.  
We show key residues (R71 and E111) that are essential for lipid-binding. Similar 
to D-e-C18-ceramide, the perturbations resulted in confined binding clusters with 
increasing amounts of FTY720 (0.5-10 µM). The shifts obtained with FTY720 also 
showed similar interaction sites as C18-ceramide along the interface between the helix of 
the dimerization domain and beta sheets in the globular region. The polar head groups of 
both compounds appear to anchor the binding along the interface between the helix of the 
dimerization domain and beta sheets in the globular region. E111 appeared to be 
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important in stabilizing the head group amine of FTY720, similar to ceramide binding. 
Data also showed that FTY720 engages with R71, while D-e-C18 ceramide did not show 
any significant association with R71. This interaction between FTY720 and R71 of SET 
appeared to be driven by an electrostatic cation/π-arene mechanism. The model also 
suggested that FTY720 is more buried in the cleft created by two anti-parallel beta sheet 
stabilized loops and an alpha helix than ceramide. Its lower molecular weight may allow 
it to better intercalate the protein. Overall, both FTY720 and ceramide are occupying the 
same region in SET, but in a different manner due to their divergent chemical structures. 
In addition, the helical structure within the dimerization domain of SET may be 
disrupted upon binding to FTY720 or ceramide, preventing oligomerization. Analysis of 
SET after crosslinking with glutaraldehyde shows a clear reduction in oligomerization. It 
is thermodynamically more plausible that oligomers are prevented from forming by a 
small molecule as opposed to disrupting oligomers. Moreover, loss of the entire N-
terminal region (Met1-Gly97) completely ablates lipid binding. Therefore, we propose 
that SET oligomerization is essential for PP2A inhibition, since SET exists primarily as a 
dimer and tetramer within cells182,242. Interestingly the SETR71A mutant showed an 
increased propensity towards the monomer state compared to SETWT and SETE111A. The 
side chain of Arg71 is perfectly situated to extend down into the globular domain of SET. 
In that position it is able to participate in electrostatic and hydrogen bonding interactions 
with Glu111 and Thr113. It is possible that this acts as a stabilization mechanism for the 
helical structure of the dimerization domain. Evidence for this can be found in Figure 30, 
where CD data of SETR71A shows that the charge loss causes SET to transition to a state 
with greater percentages of random coil and b-strands. This change, when localized to the 
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dimerization domain, could cause the R71A mutant to be more monomeric. The CD data 
further supports our proposed mechanism of a site-specific conformation transition 
centered in the dimerization domain of SET when FTY720 and C18-ceramide engage 
R71 and E111, respectively. Lipid-binding disrupts any electrostatic and hydrogen 
bonding interaction between Arg71 and Glu111 and/or Thr113. Collectively, these 
intriguing data further point to the importance of an intact N-terminal helix and 
dimerization domain for lipid-binding.  
It is important to note that the reduction in SET oligomers is not followed by a 
concomitant increase in monomeric SET. The fate of lipid-bound SET is unknown. 
Treatment with the proteasome inhibitor MG132 did not rescue monomeric SET levels 
following FTY720 exposure, suggesting the monomeric SET is not subject to increased 
proteasomal degradation. Lysosomal degradation, or autophagy, is an established 
mechanism of sphingolipid metabolism. Rare genetic mutations (Gaucher’s and Farber 
Diseases) can cause inborn errors of metabolism resulting in the accumulation of various 
sphingolipids, including ceramide258–261.  Accounting for our data suggesting the 
SET/PP2A complex may originate in the ER, it is possible that lipid-bound SET 
undergoes lysosomal degradation. Pretreatment or co-treatment of cells with Bafilomycin 
A1, a vacuolar proton ATPase inhibitor, with FTY720 may inhibit lysosomal262 
degradation and possibly restore monomeric SET. If lipid-bound SET transitions to a 
state more similar to random coil, it is possible that the UPR pathway is responsible for 
clearing the protein in order to avoid ER stress. SET dimerization has been shown to 
influence inhibitor of histone acetyltransferases (INHAT) function151,235, it is also 
possible that SET regulates its own transcription through an epigenetic mechanism. 
 137 
In this study, we used a pyridinium ceramide as a molecular probe to test our 
‘extended’ ceramide structure hypothesis97. NMR data showed that a particular proton on 
the pyridine ring had weak NOEs with both the alpha hydroxyl and aliphatic chain of the 
sphingosine base. This is indicative of transient proximity caused by rotation around the 
amide bond. Upon binding to SET, that rotation is stabilized into the ‘extended’ 
conformation, allowing protons on the pyridine ring to undergo efficient magnetization 
transfer when monitored by STD-NMR. If the ceramide were ‘compact’, magnetization 
transfer would be inefficient or non-existent due to steric hindrance caused by the 
sphingosine backbone. TOCSY analysis of FTY720 showed that the amine group, 
followed by the aromatic ring, initiates binding to SET. We were also able to gain insight 
into the stereochemical specificity that SET displays. When the chirality at carbons 2 and 
3 on the sphingosine backbone are changed from 2S,3R (D-erythro) to 2R,3S (L-threo) 
the sphingosine backbone is not able to align in parallel with the N-terminal helix. 
Instead, the sphingosine backbone shifts perpendicular to the N-terminal helix, and 
possibly interferes with the polar head group’s ability to engage the binding pocket (data 
not shown). Additionally, the ‘handedness’ of the N-terminal helix creates charge 
distribution through spin polarization, providing enantioselectivity263.  
It is interesting to note that despite both SET and PP2A being in high abundance 
in cells, there is only a limited interaction between the two proteins, as evidenced by 
PLA. This suggests that the interaction may be more specific and that SET may not be a 
universal inhibitor of PP2A, as is widely believed. Our data show that the loss of specific 
PP2A subunits will disrupt SET-PP2A association, proposing that SET inhibits a 
particular PP2A consisting of PP2AA, B56γ, and PP2ACα subunits. Literature indicates 
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that this PP2A, containing the B56γ regulatory subunit, is important for tumor 
suppression in many types of malignancies130. Its dysregulation, either by mutation or 
over expression, ablates PP2A’s anti-tumor capabilities129,131,133,264. Based on our data, at 
least a monomer of SET remains with FTY720-activated PP2A by maintaining contact 
with the B56γ subunit. This apparent complex may be a mode of regulation, where PP2A 
can be turned off by SET oligomerization. Further studies are needed to describe the 
molecular details of the SET/ B56γ interaction.  
This study relies on proximity ligation assays to look at protein-protein 
association in cells. While more precise than traditional immune fluorescence due to the 
necessity of targets to be within 40nm of each other, there are some weaknesses in the 
technique that need to be addressed. Foremost, the strength of the assay is lies in the 
quality/specificity of the primary antibodies being used. It is necessary to test via Western 
blot and immune-precipitation prior to use in PLA. If the antibody is not specific, then 
the results collected by PLA are not reliable. Another limitation is that this technique is 
semi-quantitative. The analysis software relies on manually set thresholds and puncta 
sizes. This sometimes results in either an over or under estimating of signal number.  
Alternatively, a bioluminescence resonance energy transfer (BRET) or 
fluorescence resonance energy transfer (FRET) system could be used to look at protein-
protein interactions. These systems are labor intensive due to the amount of cloning 
needed to construct the various combinations of fusion proteins. They are also very 
difficult to optimize because of the necessity to test combinations of N-terminal or C-
terminal fusion proteins. A concern specific to SET and PP2A is the paucity of overall 
interaction. The resonance transfer may not result in consistently detectable signals. That 
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leaves us with in vitro binding assays. This requires the purification of all relevant PP2A 
subunits, the PP2AA, B56γ, and PP2ACα subunits, some of which require insect cell 
lines for expression. Moreover, a leucine carboxyl methyltransferase (LCMT) needs to be 
purified so that the C-terminal lysine of PP2ACα can be primed before assembly of the 
holoenzyme140,141. Traditional techniques such as surface plasmon resonance (SPR) and 
isothermal titration calorimetry (ITC). Both techniques require large amounts of protein 
that are quickly exhausted. Ultimately, PLA in combination with these in vitro assays 
would provide very strong evidence for SET being an inhibitor of a specific PP2A 
holoenzyme. 
The data also show that the knockdown of B56γ completely ablates PP2A activity 
after exposure to FTY720, shown by monitoring total PP2A p-Tyr307 levels. This is very 
interesting and unexpected. Not only does it point to the specificity of SET; it may 
suggest that this particular PP2A plays a more important role in the overall regulation of 
the various PP2A species in the cell. The idea of a ‘master-regulator PP2A’ is very 
intriguing and deserves further investigation. 
Interestingly, the phosphorylation status of SET at Ser171 also plays key roles in 
determining SET-PP2A association. In fact, while S171E had no effect on FTY720-
mediated PP2A activation, S171A-SET was resistant to FTY720-mediated PP2A 
activation, which stayed associated with both PP2ACα and PP2A-B56γ subunits as an 
oligomeric protein with/without FTY720 in A549 cells. These data further support the 
idea that the oligomerization state of SET determines its association with PP2A, and that 
inhibition of SET- PP2ACα results in PP2A activation against specific downstream target 
proteins.    
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To this end, we determined that Myosin IIa, identified via SILAC mass 
spectrometry analysis, as a potential target of B56γ-containing PP2A. Myosin IIa has 
been identified as a tumor suppressor in squamous cell carcinoma257. There is evidence 
that PP2A-dependent dephosphorylation of myosin IIa exerts some influence over 
filament assembly265. However, the molecular details of how PP2A affects myosin IIa to 






































Figure 57| Working model of SET-dependent PP2A activation 
The SET/ PP2A complex assembles in the endoplasmic reticulum. PP2A is inhibited by 
oligomeric SET. Increase in intracellular ceramide or exogenous exposure to FTY720 
causes SET to become ligand-bound. Ligand-bound SET undergoes a site-specific 
conformational change from a-helix to random coil in the N-terminal dimerization 
domain. This prevents SET oligomerization, resulting in the activation of PP2A. The 
monomer-SET/PP2A  complex then transitions from the ER to the Golgi when it targets 
























SET overexpression has been identified in many cancer types. The therapeutic 
value of targeting SET, genetically or pharmacologically, to reactivate tumor suppressor 
PP2A has been shown in many cancer models. Nevertheless, there are no commercially 
available SET-targeting therapeutics due in large part to a lack of knowledge regarding 
SET/PP2A interaction and SET/ceramide interaction. Since FTY720 and its myriad 
derivatives are heavily patented by Novartis, the information obtained from this study 
will provide the foundation for the development of FTY720/ceramide mimetics as novel 
SET inhibitors to reactivate tumor suppressor PP2A. 
We are using the NMR-guided models to drive the discovery/development of 
novel SET-targeting therapeutics. To begin, we ran over 300,000 simulations using an in-
house chemical library of over 100,000 compounds. The compounds were ranked by 
Escore2, and the top 1,200 were re-docked with a higher stringency. This resulted in 125 
significant compounds, which were further pruned based on compound chemistry. The 
compounds then need to be validated for binding and functionality. In this case, we can 
use ligand-observed NMR to look for binding events with SET. Chemical shifts and line 
broadening of the test compound’s 1D are monitored. As a functional assay, we plan to 
use both PLA and a PP2A assay. Both can be adapted to achieve reasonably high 
throughput. We would look for an increase in PP2A activity to coincide with a loss of 
PLA signal when monitoring the association of endogenous SET and PP2AC. Lead 
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compounds would then be subjected to more vigorous biophysical analyses, such as SPR 
or ITC testing protein-ligand interaction. 
An additional avenue of drug discovery is fragment-based screening. This method 
entails testing chemical moieties against protein while collecting 2D NMR data. 
Chemical shifts or monitored, much like for the studies outlined in Chapter 4. This 
method allows for the identification of weak binders that other biophysical analyses 
might otherwise miss. Fragment screening also allows one to access a greater fraction of 
chemical diversity, with a relatively small screening library. Typically, multi-site binding 
occurs for each functional group266. From there, the functional groups can be modeled 
into the protein based on their CSP fingerprint and a compound can then be built by 
chemically ‘connecting’ them. This results in a novel compound with the bare minimum 
structure needed to hit the target. The major drawback to this method is it requires a lot of 
protein to screen hundreds or thousands of fragments. The lack of a Sample Jet also limits 
feasibility because automation of the process allows for 24 hour data collection. For these 
reasons, we decided that a compound-based approach would be the best avenue of drug 
discovery. This study is in the very early stages and ongoing. 
Since SET is found to be overexpressed in many cancers, a SET-targeted therapy 
could be widely used. SET overexpression could easily be tested for through biopsy and 
immunohistochemistry or Western blot comparing cancerous tissue to normal tissue. If 






Define How PP2AC targets Myosin IIa 
 
We determined that Myosin IIa, identified via SILAC mass spectrometry analysis, 
is a potential target of FTY720-activated, B56γ-containing PP2A. Myosin IIa has been 
identified as a tumor suppressor in squamous cell carcinoma257. Specifically, the 
disruption of ER to Golgi vesicular trafficking caused by the loss of myosin IIa was 
tumor suppressive257. It was recently shown that RAB 6 and 6a recruit myosin IIa to 
stimulate fission of vesicles budding from the trans-Golgi network267. There is also 
evidence that PP2A-dependent dephosphorylation of myosin IIa exerts some influence 
over myosin IIa filament assembly265. However, the molecular details of how PP2A 
affects myosin IIa to drive tumor suppression are unknown and warrant further 
investigation.  
Since there is very little literature on PP2A and myosin IIa, finding the 
phosphorylation site on myosin IIa would be imperative to describing their interaction. A 
mass spectrometry (MS) based approach would be the best route of analysis. Immune 
precipitation of myosin IIa in vehicle and FTY720 treated cells, followed by MS analysis 
of each sample may identify differentially phosphorylated serine or threonine. We would 
expect reduced phosphorylation on serines or threonines targeted by FTY720-activated 
PP2A. Conversely, one could treat cells with the PP2A inhibitor, okadaic acid, and look 
for higher levels of phosphorylation compared to vehicle controls. All potential target 
residues would need to be mutated, and the experiment repeat for each myosin IIa mutant 
to confirm the residue(s) as a PP2A site. 
Unpublished data from the lab shows that treatment of cancer cells with FTY720 
causes D-e-C16 ceramide to be transported to the plasma membrane. Importantly,  
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brefeldin A, an inhibitor of ER to Golgi vesicular trafficking, abrogates FTY720-induced 
ceramide transport. Additionally, the knockdown of myosin IIa in cancer cells completely 
disrupts FTY720-induced D-e-C16 ceramide transport. Conceivably, the SET/PP2A 
complex could play a role in the transport of C16 ceramide to the plasma membrane by 
regulating Rab6/myosin IIa function. 
Perhaps PP2A targets Rab6 directly and not myosin IIa. In a yeast model, serine 
phosphorylation of Rab 6 ortholog, Sec4p, negatively regulates activity necessary for cell 
viability268. Furthermore, evidence suggests that the phosphorylation status of Sec4p is 
governed by an unknown PP2A holoenzyme268. There are multiple reports of Rab family 
proteins being regulated by phosphorylation268–273; however, the opposing phosphatase(s) 
remains undescribed. Some literature also suggests that PP2A can target other GTPases 
RalA and Rac1116,274, the latter of which facilitates the migration of a SET/PP2A complex 
to the plasma membrane.  
 
Characterize and examine the possibility of the SET/PP2A complex assembling in 
the endoplasmic reticulum  
 
The question always lingering around the SET/PP2A field is where does SET find  
ceramide? The simplest answer would be the ER, the main source of ceramide within 
cells. Ceramide levels can be regulated to rapidly increase or decrease in order to regulate 
the activity of tumor suppressive PP2A. Increased ceramide levels would inhibit SET 
oligomerization, and activate PP2A, while decreased ceramide levels would promote SET 
oligomerization which results in inhibition of PP2A activity. This is an efficient 
mechanism to regulate a very important enzyme in the cell. In this study, we show data 
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that suggest the SET/PP2A complex is localized in ER and can egress to the Golgi upon 
stimulus with FTY720 or DeC18. The ER localization of the SET/PP2A complex is 
plausible if it plays a role in the transport of C16 ceramide to the plasma membrane by 
regulating Rab6/myosin IIa function discussed in the previous section.  
CERS6/C16-ceramide expression protects against ER stress by activating the 
ATF6/CHOP unfolded protein response pathway45. If lipid-bound SET transitions to a 
state more similar to random coil, it is possible that the UPR pathway is responsible for 
clearing the protein in order to avoid ER stress. Perhaps the mobilization of C16 
ceramide has a twofold affect: disruption of plasma membrane integrity causing cell 
rupture and initiation of the UPR pathway to dispose of lipid-bound SET. In this case, 
brefeldin A could be used to induce the UPR pathway in conjunction with FTY720 after 
pre-treatment of cells with cycloheximide. The ER could be isolated by differential 
centrifugation to examine potential SET accumulation.  
It is possible that the SET-PP2A complex/Rab6/myosin IIa/C16 ceramide axis is 
meant to maintain membrane fluidity under homeostatic physiological condition by 
transporting long chain ceramides275,276. However, overabundance of SET or exogenous 
cell stress (FTY720) can manipulate this pathway to support pro-survival or tumor 
suppressive roles.  
 
 
Describe How SET interacts with the B56g subunit of PP2A 
 
Unexpectedly, we noted that at least a monomer of SET remains with FTY720-
activated PP2A by maintaining contact with the B56γ subunit. This apparent complex 
may be a mode of regulation, where PP2A can be turned off by SET oligomerization.  
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X-ray crystallography would be the best way to examine the interaction between SET and 
B56g. Crystallization of the SET/B56g complex and SET/PP2A holoenzyme (consisting 
of PP2AA, B56γ, and PP2ACα subunits) in the presence and absence of FTY720 or 
DeC18 ceramide would provide details for this study. This study would require the 
purification of all relevant PP2A subunits, PP2AA, B56γ, and PP2ACα subunits, some of 
which require insect cell lines for expression. Moreover, a lysine methyltransferase 
(LMT) needs to be purified so that the C-terminal lysine of PP2ACα can be primed 
before assembly of the holoenzyme. In addition to setting crystal screens for the afore 
mentioned complexes, one could also try to crystalize the SET/PP2A holoenzyme 
complex in conditions previously published for the holoenzyme alone115. Literature 
suggests that multi-wavelength anomalous diffraction (MAD) would be required to 
resolve the phase problem along with molecular replacement to generate a structure due 
to the size of the SET/PP2A complex115,141,277,278. 
 The molecular replacement method is a common tool to overcome the phase 
problem in X-ray crystallography. The phase problem is the ability to only measure the 
amplitude of a wave and not its origin after diffraction. The origin determines where 
wave maxima occur and does not influence the amplitude of a wave. This means phase 
can make waves constructive, giving strong diffraction, or destructive, the latter resulting 
in weak diffraction and lost information pertaining to electron density (structure). If the 
structure of a homologous protein has already been solved, the phase information from 
that protein can be superimposed onto collected diffraction data to generate an initial 
phase and electron density for the unknown structure279. This method requires high 
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homology between proteins to avoid introducing bias when generating a structure. If 
structure factors (F-values are representations of reflection phases and amplitudes) are 
too different, then the method can fail to produce an initial electron density280.  
Multi wavelength anomalous diffraction (MAD) with selenomethionine 
replacement of  methionine can also resolve the phase problem. Heavy atoms (selenium) 
have a delayed emission of certain wavelength X-rays, which causes phase shifts in all 
reflections281. The analysis of these phase shifts at varying wavelengths can resolve the 
phase problem and provide an initial phase for the entire protein. Heavy atoms scatter X 
rays more strongly, so the wave amplitude changes. Comparison of the native protein and 
heavy protein structure factors are then used to geometrically solve the phase based on 
constructive or destructive diffraction279. If crystallography proves unfruitful, high 
resolution cryo-electron microscopy would be a potential alternative to obtain structure of 
the SET/PP2A holoenzyme. 
Once structures are solved, point mutations need to be made at contact points 
between SET and B56g. These mutations need to be validated structurally, and then 
introduced to cell systems for functional bioassays. PLA could be used to examine the 
effect the mutations have mon association between SET and PP2AC and SET and B56g. 
These studies could be coupled with PP2A activity assays. The structural details gained 
from this study would identify the interface of SET and B56g interaction. Drug discovery 
studies could then be undertaken to target this region, leading to the inability of SET to 
interact with PP2A and subsequent PP2A activation. The combinatorial approach of 
structural and molecular biology would not only enhance knowledge in the PP2A field, 
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but also be used to design a novel SET-targeting drug to reactivate PP2A through a 
completely different mechanism. 
 
 
Further investigate how lipid-binding affects SET oligomerization 
 
 Some additional work could be done to further describe how lipid binding effects 
SET oligomerization. Triple resonance NMR experiments can be performed in the 
absence and presence of FTY720. Backbone chemical shifts can be processed to calculate 
a random coil index (RCI). RCI calculates protein flexibility by computing an inverse 
weighted average of backbone secondary chemical shifts and predicting values of model-
free order parameters as well as per-residue RMSD of NMR datasets282. The expected 
result would be that the addition of FTY720 causes N-terminal residues in the 
dimerization domain to index more similarly with random coil than a-helix. If the 
SETR71A mutant is able to be crystalized, the structure may support the mechanism 
proposed earlier in the chapter. BRET studies of SETWT and SETR71A could potentially be 
used in cells to support the biological relevance of Arg71 and its role in SET 
oligomerization. In SET knockdown cells various combinations of N-terminal or C-
terminal GFP2 fusion SET could be tested in the absence and presence of FTY720 or 
DeC18 ceramide. We would be looking a loss of GFP signal during exposure to FTY720 
or DeC18 ceramide. These data from proposed experiments combined with the data 
presented here would add valuable information to the understanding of SET regulation of 
PP2A activity.  
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Overall, there are important implications of the data reported here with regards to 
understanding PP2A regulation and tumor suppression283 by providing the molecular 
details of interactions between SET and PP2A, or SET-ceramide/FTY720. The structural 
information obtained concerning the lipid-binding pocket of SET will provide the 
foundation for the development of FTY720/ceramide analogs as novel SET inhibitors to 
reactivate tumor suppressor PP2A with improved specificity and anti-cancer function, 









































































Protocols for the Purification of Recombinant SET Constructs 
 
Purification of Nd-SET 
 
  
Nd-SET was cloned into a pET-22b (+) vector after PCR amplification with the 
following primers:  
Forward: 5' CAGTAGCACATATGACCTCAGAAAAAGAACAGCAAGAAG 3' 
Reverse: 5' GTCCTCGAGTTAGTCATCTTCTCCTTCATCCTCCTC 3' 
BL21 (DE3) pLys cells were transformed and grown in Luria-Bertani (LB) media at 
37°C with 100µg/ml ampicillin. Protein expression was induced with 0.03 mM IPTG 
overnight at 18˚C, with shaking at 190rpm. The cells were collected and resuspended in 
10mM Na phosphate pH 8.0, 500mM NaCl, 20mM imidazole, 2% glycerol, 0.1% triton-
X 100, and 0.5mM PMSF. Cells were lysed by sonication, and the lysate was then 
clarified by centrifugation at 15,000 rpm for 75 minutes at 4˚C. The clarified cell lysates 
were then filtered through 0.22µm membrane. 
The protein was loaded onto a sepharose Fast Flow HisTrap column (GE 
Healthcare) and eluted using a linear gradient ending at 500mM imidazole (Fig. 44). The 
pooled fractions were then dialyzed overnight at 4°C into phosphate buffer (10 mM 














Figure 58| Elution of Nd SET from nickel affinity column. 
The imidazole gradient runs from 50mM to 500mM. Nd-SET elutes from the column at approximately 


































Purification of NdCd-SET 
 
NdCd-SET was cloned into a pET28b (+) vector after PCR amplification with the 
following primers:   
Forward: 5' CGCGTGGTTCCCATATGGAAAACCTGTACTTCCAATCACCTCAGAAAAAGAACA 3' 
Reverse: 5' GATCCTTACTACATATCACATATCGGGAACCAAGTA 3' 
 
BL21 (DE3) pLys cells were transformed and grown in Luria-Bertani (LB) media at 
37°C with 100µg/ml kanamycin. Protein expression was induced with 0.03 mM IPTG 
overnight at 18˚C, with shaking at 190rpm. The cells were collected and resuspended in 
10mM Na phosphate pH 8.0, 500mM NaCl, 20mM imidazole, 2% glycerol, 0.1% triton-
X 100, and 0.5mM PMSF. Cells were lysed by sonication, and the lysate was then 
clarified by centrifugation at 15,000 rpm for 75 minutes at 4˚C. The clarified cell lysates 
were then filtered through 0.22µm membrane. 
The protein was loaded onto a sepharose Fast Flow HisTrap column (GE 
Healthcare) and eluted using a linear gradient ending at 500mM imidazole (Fig. 45a). 
The pooled fractions were incubated overnight at 4˚C with Thrombin to cleave the 6X-
Histidine tag (Fig. 45b). The cleaved protein was then injected onto a HiLoad 26/60 200 
prep grade column pre-equilibrated with phosphate buffer (10 mM phosphate buffer, 50 





Figure 59| Elution of NdCd SET from nickel affinity column. 
a, The imidazole gradient runs from 50mM to 500mM. NdCd-SET elutes from the column at 
approximately 200mM imidazole. b, Pooled fractions of NdCd-SET pre-and post-overnight thrombin 











Figure 60| Elution of NdCd SET from gel filtration column. 
Thrombin-cleaved NdCd-SET loaded onto and eluted from a HiLoad 26/60 200 prep 





Purification of TRUNC SET 1 
 
TRUNC SET 1 was cloned into a pHGK vector using the following primers: 
FORWARD: 5' CGCGTGGTTCCCATATGGAAAACCTGTACTTCCAATCACCTCAGAAAAAGAACAGCAAGA 3' 
REVERSE: 5' GATCCTTACTACATATCAGTAAGGATTTTCATCAAAATAAAAATCTATTCTGTAACCTG 3' 
BL21 (DE3) pLys cells were transformed and grown in 15N-labeled M9 minimal media at 
37°C with 100µg/ml kanamycin. The cells were grown to high density OD600 = 0.8 before 
protein expression was induced with 0.03 mM IPTG overnight at 18˚C, with shaking at 
190rpm. The cells were collected and resuspended in 10mM Na phosphate pH 8.0, 
500mM NaCl, 20mM imidazole, 2% glycerol, 0.1% triton-X 100, and 0.5mM PMSF. 
Cells were lysed by sonication, and the lysate was then clarified by centrifugation at 
15,000 rpm for 75 minutes at 4˚C. The clarified cell lysates were then filtered through 
0.22µm membrane. 
The protein was loaded onto a sepharose Fast Flow HisTrap column (GE 
Healthcare) and eluted using a three step gradient beginning at 50mM imidazole, primary 
elution at 250mM imidazole, and ending at 500mM imidazole (Fig. 47). The pooled 
fractions were incubated overnight at 4˚C with TEV protease with 1 mM DTT to cleave 
the 6X-Histidine tagged-GB1 (Fig. 48). TRUNC SET 1 precipitates over a 24-hour 
period, speeding up upon cleavage of GB1 (Fig. 48). The addition of L-arginine or L-
glutamine to stabilize charges did not prevent precipitation. Adjusting the pH (either 
more acidic or basic) had no effect.  
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Figure 61| Elution of GB1-TRUNC SET 1 fusion protein from nickel affinity 
column. 
The primary elution of protein occurs at 250mM imidazole between fractions 16-26, with 
a secondary elution from fraction 28 at 500mM imidazole. Fractions 16-28 were pooled 
for overnight TEV protease cleavage.  
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Figure 62| Elution of cleaved GB1 from nickel affinity column. 
The gel image shows products that result from TEV cleavage. The black arrow points to 
uncleaved GB1-TRUNC SET 1 fusion protein. The green arrow points to GB1. The red 
arrow indicates precipitated TRUNC SET 1. Precipitated TRUNC SET 1 was removed 
and the remaining sample was loaded onto the column. GB1 was the primary eluent at 
250mM imidazole.  
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Purification of TRUNC SET 2 
 
TRUNC SET 2 was cloned into a pHGK vector using the following primers: 
Forward: 5' CGCGTGGTTCCCATATGGAAAACCTGGTACTTCCAATCAGGGGAGGAAGATGAAGAGGCAC 3' 
Reverse: 5' GATCCTTACTACATATCATCCTTCATCATCCATATC 3' 
BL21 (DE3) pLys cells were transformed and grown in 13C-15N labeled M9 minimal 
media at 37°C with 100µg/ml kanamycin. The cells were grown to high density OD600 = 
0.8 before protein expression was induced with 0.03 mM IPTG overnight at 18˚C, with 
shaking at 190rpm. The cells were collected and resuspended in 10mM Na phosphate pH 
8.0, 500mM NaCl, 20mM imidazole, 2% glycerol, 0.1% triton-X 100, and 0.5mM PMSF. 
Cells were lysed by sonication, and the lysate was then clarified by centrifugation at 
15,000 rpm for 75 minutes at 4˚C. The clarified cell lysates were then filtered through 
0.22µm membrane. 
The protein was loaded onto a sepharose Fast Flow HisTrap column (GE 
Healthcare) and eluted using a three step gradient beginning at 50mM imidazole, primary 
elution at 250mM imidazole, gradient ending at 500mM imidazole (Fig. 49). The pooled 
fractions were incubated overnight at 4˚C with TEV protease with 1 mM DTT to cleave 
the 6X-Histidine tagged-GB1 (Fig. 50). Cleaved protein was again passed through a 
sepharose Fast Flow HisTrap column (GE Healthcare) to remove GB1 and TEV. The 
flow through was collected as the final purification product. The cleaved TRUNC SET 2 
was then dialyzed overnight at 4˚C in phosphate buffer (10 mM phosphate buffer, 50 mM 




Figure 63| Elution of GB1-TRUNC SET 2 fusion protein from nickel affinity 
column. 
The primary elution of protein occurs at 250mM imidazole between fractions 16-26, with 
a secondary elution from fraction 28 at 500mM imidazole. Fractions 16-28 were pooled 
for overnight TEV protease cleavage.  
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Figure 64| Elution of cleaved GB1 from nickel affinity column. 
Cleaved TRUNC SET 2 was collected in the flow through following TEV cleavage and 
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Purification of TRUNC SET 3 
 
TRUNC SET 3 was cloned into a pHGK vector using the following primers: 
Forward: 5' CGCGTGGTTCCCATATGGAAAACCTGTACTTCCAATCAGGTGCTGATGAGTTAGGA 3' 
Reverse: 5' GATCCTTACTACATATCAGTCATCTTCTCCTTCATCCTCCTC 3' 
BL21 (DE3) pLys cells were transformed and grown in 13C-15N labeled M9 minimal 
media at 37°C with 100µg/ml kanamycin. The cells were grown to high density OD600 = 
0.8 before protein expression was induced with 0.03 mM IPTG overnight at 18˚C, with 
shaking at 190rpm. The cells were collected and resuspended in 10mM Na phosphate pH 
8.0, 500mM NaCl, 20mM imidazole, 2% glycerol, 0.1% triton-X 100, and 0.5mM PMSF. 
Cells were lysed by sonication, and the lysate was then clarified by centrifugation at 
15,000 rpm for 75 minutes at 4˚C. The clarified cell lysates were then filtered through 
0.22µm membrane. 
The protein was loaded onto a sepharose Fast Flow HisTrap column (GE 
Healthcare) and eluted using a three step gradient beginning at 50mM imidazole, primary 
elution at 250mM imidazole, gradient ending at 500mM imidazole (Fig. 51). The pooled 
fractions were incubated overnight at 4˚C with TEV protease with 1 mM DTT  to cleave 
the 6X-Histidine tagged-GB1 (Fig. 52). Cleaved protein was again passed through a 
sepharose Fast Flow HisTrap column (GE Healthcare) to remove GB1 and TEV. The 
flow through was collected as the final purification product. Cleaved TRUNC SET 3 was 
then dialyzed overnight at 4 ˚C into phosphate buffer (10 mM phosphate buffer, 50 mM 
NaCl pH 8.0). 
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Figure 65| Elution of GB1-TRUNC SET 3 fusion protein from nickel affinity 
column. 
The primary elution of protein occurs at 250mM imidazole between fractions 16-22. 
Fractions 16-21 were pooled for overnight TEV protease cleavage. 
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Figure 66| Elution of cleaved GB1 from nickel affinity column. 
Cleaved TRUNC SET 1 was collected in the flow through following TEV cleavage and 
loading the nickel affinity column. GB1 was the primary eluent at 250mM imidazole. 
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Recipe for M9 Minimal Media to Make Isotopically Labeled Protein 
 
 
Solution A  (autoclave sterilize) 
 
Na2HPO4 (anhydrous)  14.6g 
KH2PO4 (anhydrous)     5.4g 
NH4Cl       1.0g  15N labeled Ammonium Chloride 
dH2O     975ml 
 





Glucose      4.0g *(2.0g if 13C-glucose) 
MgSO4    240mg 
Thiamine hydrochloride    20mg 
The following are made up as stock solutions and will last years: 
5g/l MnSO4    0.5ml 
37.5g/l CaCl2    0.5ml 
1g/l FeCl2    0.5ml 
 
Antibiotic of choice 
 














Conditioning and Growth Protocol for Bacterial Cultures in Deuterium 




All glassware must be autoclaved, rinsed with  95% D2O, and dried with Nitrogen gas to 
retain hygroscopic conditions and not dilute the deuterons. Media preparation is the same 
as traditional M9 media outlined on the previous page except all stocks are made in 
99.99% D2O. 
 
§ Day 1 (evening): Grow cells overnight from a glycerol stock in LB at 37°C 
§ Day 2 (morning): Add 200 µL of LB culture to 1.8 mL 35% D2O 2H-M9 for 25% 
final concentration of D2O. Grow cells overnight at 37°C. 
§ Day 3 (morning): Add 200 µL of 25% 2H-M9 culture to 1.8 mL 80% D2O 2H-M9 
for 75% final concentration of D2O. Grow cells overnight at 37°C. 
§ Day 4 (morning): Add 200 µL 75% 2H-M9 culture to 7mL of 100% 2H-M9. Grow 
cells for 8+ hours at 37°C. 
§ Day 4 (evening): Add 5mL of the 99% 2H-M9 culture to 50mL 100% 2H-M9 
culture with labeled isotopes. Grow cells to high density overnight at 37°C. 
§ Day 5 (morning): Add 25 mL of 99.9% 2H-M9 culture to each 2L flask. Grow at 
37°C until OD600 reaches 0.8.  
§ Day 5 (evening): Induce expression with 0.03 mM IPTG overnight at 18˚C, with 

















































































































































































































































































List of shRNA Sequences Used in the Generation of Stable Cell Lines 
 


















































Figure 67| Knockdown efficiency of PP2A-related subunits. 
(a) Western blot analysis of stable A subunit knockdown in shPP2AA⍺ and shPP2Aβ 
A549 cells. (b) Quantitation of PP2AA knockdown normalized to actin. (c) Western blot 
analysis of stable B subunit knockdown in shB56ɣ and shB56𝛿 A549 cells. (d) 
Quantitation of B56ɣ and B56𝛿 knockdown. (e) Western blot analysis of stable PP2AC 
knockdown in shPP2AC⍺ and shPP2ACβ A549 cells. (g) Quantitation of PP2AC 
knockdown efficiency normalized to actin. 
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